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To investigate mechanisms of HIV-1 resistance to 3’-azidonucleoside analog reverse 
transcriptase inhibitors, in vitro selection experiments were conducted by serial passage of HIV-
1LAI in MT-2 cells in increasing concentrations of 3′-azido-2′,3′-dideoxyguanosine (3′-azido-
ddG), 3′-azido-2′,3′-dideoxycytidine (3′-azido-ddC), or 3′-azido-2′,3′-dideoxyadenosine (3′-
azido-ddA). 3′-Azido-ddG selected for virus 5.3-fold resistant to 3′-azido-ddG. Population 
sequencing of the reverse transcriptase (RT) gene identified L74V, F77L, and L214F mutations 
in the polymerase domain and K476N and V518I mutations in the RNase H domain. Site-
directed mutagenesis showed that these 5 mutations only conferred ~2.0-fold resistance. Single-
genome sequencing analyses revealed a complex population of mutants that all contained L74V 
and L214F linked to other mutations, including ones not identified during population sequencing. 
Recombinant HIV-1 clones containing RT derived from single sequences exhibited 3.2- to 4.0-
fold 3′-azido-ddG resistance. By contrast, 3′-azido-ddC selected for the V75I mutation in HIV-1 
RT that conferred 5.9-fold resistance. We were unable to select HIV-1 resistant to 3′-azido-ddA, 
even at concentrations of 3′-azido-ddA that yielded high intracellular 3′-azido-ddA-5′-
triphosphate levels. We have also defined the molecular mechanisms of 3’-azido-ddG resistance 
by performing in-depth biochemical analyses of HIV-1 RT containing mutations 
L74V/F77L/V106I/L214F/R277K/K476N (SGS3). The SGS3 HIV-1 RT was from a single-
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genome-derived full-length RT sequence obtained from 3’-azido-ddG resistant HIV-1 selected in 
vitro. We also analyzed two additional constructs that either lacked the L74V mutation (SGS3-
L74V) or the K476N mutation (SGS3-K476N). Pre-steady-state kinetic experiments revealed 
that the L74V mutation allows HIV-1 RT to effectively discriminate between the natural 
nucleotide (dGTP) and 3’-azido-ddG-triphosphate (3’-azido-ddGTP). 3’-azido-ddGTP 
discrimination was primarily driven by a decrease in 3’-azido-ddGTP binding affinity (Kd) and 
not by a decreased rate of incorporation (kpol). The L74V mutation was found to severely impair 
RT’s ability to excise the chain-terminating 3’-azido-ddG-monophosphate (3’-azido-ddGMP) 
moiety. However, the K476N mutation partially restored the enzyme’s ability to excise 3’-azido-
ddGMP on an RNA/DNA, but not on DNA/DNA, template/primer by selectively decreasing the 
frequency of secondary RNase H cleavage events. Taken together, these data provide strong 
additional evidence that the nucleoside base structure is major determinant of HIV-1 resistance 
to the 3’-azido-2’,3’-dideoxynucleosides that can be exploited in the design of novel nucleoside 
RT inhibitors. 
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1.0  INTRODUCTION TO THE HUMAN IMMUNODEFICIENCY VIRUS AND 
ANTIRETROVIRAL THERAPY 
The clinical presentation of previously healthy homosexual men and intravenous drug users 
displaying infections of opportunistic diseases and decreased T-cell counts marked the onset of 
the global pandemic now known as Acquired Immunodeficiency Syndrome (AIDS) [1-3]. The 
etiological agent was isolated from infected individuals and independently discovered to be the 
human immunodeficiency virus (HIV) [4,5]. Life-long antiretroviral therapy can delay disease 
progression, but current drugs are limited by the development of viral drug resistance and by 
toxicity of the drugs on the host [6]. To date, HIV remains an incurable infection and there are no 
effective vaccines available. Although dozens of FDA approved antiretroviral compounds exist, 
a comprehensive knowledge of HIV molecular virology can lead to the rational design of novel 
compounds that with stronger antiviral activity, less sensitivity resistance and diminished toxicity 
profiles. 
1.1 HUMAN IMMUNODEFICIENCY VIRUS 
HIV is an enveloped, single-stranded, positive-sense, RNA virus that is a member of the 
lentivirus genus of the family Retroviridae. The replication strategy of these viruses requires 
reverse transcription of the RNA genome into double stranded DNA by the viral enzyme reverse 
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transcriptase [7,8]. Two genetically distinct types of HIV have been identified that originated in 
isolated primate reservoirs; HIV type 1 (HIV-1) and HIV type 2 (HIV-2). HIV-1 can be further 
divided into four groups, main (M), non-M non-O (N), outlier (O), and putative (P) based on the 
genetic differences [9-11]. Group M subtypes (A–D, F, G, H, J, and K) are spread globally, 
Figure 1, and originated in the chimpanzee (Pan troglodytes troglodytes) [12-16]. HIV-1 subtype 
B is responsible for most infections in industrialized nations and is a often used as the model 
virus for research, although HIV-1 subtype C dominates most of the global infections [17]. HIV-
2 subtypes are mainly restricted to West Africa and can be characterized as epidemic subtypes 
(A and B) and non-epidemic subtypes (C–G) [18] and originated in the sooty mangabey 
(Cercocebus torquatus atys) [19-23]. The endemic restriction of HIV-2 may be due to its lower 
pathogenicity over HIV-1 [24].   
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Figure 1: Global distribution of HIV-1 subtypes and recombinants 
The map was divided into 15 regions consisting of groups of countries shaded in the same color. 
Pie charts representing the distribution of HIV-1 subtypes and recombinants in each region in 
2004–2007 are superimposed on the regions. The colors representing the different HIV-1 
subtypes are indicated in the legend on the left-hand side of the figure. The relative surface areas 
of the pie charts correspond to the relative numbers of people living with HIV in the regions 
CRF, circulating recombinant form; URF, unique recombinant form. Reprint with permission 
from Hemelaar, J., et al. 2011 [17]. 
1.1.1 Viral genome 
Each individual HIV virion carries two copies of a positive-sense, single-stranded mRNA 
genome that are 5’-7-methylguanylate capped and 3’-polyadenylate tailed [25-27]. The complete 
9.2 kb genome of HIV-1 has been sequenced and contains the classic retroviral gag-pol-env 
structural and enzymatic encoding genes, as well as additional regulatory and accessory genes, 
Figure 2 [28].  
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 Figure 2: Genome organization of HIV-1 and SIV/HIV-2 
Open reading frames that encode proteins that are efficiently incorporated into virions are in 
blue; those encoding regulatory proteins are in red; and those encoding other auxiliary proteins 
are in green. The different vertical positions denote different reading frames. The long terminal 
repeats (LTRs), shaded grey, contain sequences necessary for transcriptional initiation and 
termination, integration and binding the viral transactivator Tat. 
 
The structural gene products are encoded collectively by gag and env. The gag gene is 
transcribed from unspliced viral mRNA into the Gag precursor protein, p55. Gag is 
myristoylated at the N-terminal glycine residue that is required for stable cytoplasmic membrane 
association and virion assembly [29]. After budding, Gag is specifically cleaved by the virally 
encoded protease into four proteins designated from N-terminal to C-terminal: matrix (MA, p17), 
capsid (CA, p24), nucleocapsid (NC, p7) and p6 [30]. After cleavage, most MA remains 
anchored to the inner surface of the virion membrane where it provides support to the virion 
structure, however a fraction of MA is incorporated into the virion core in association with 
integrase [31]. Before cleavage, the CA-region of Gag binds the cellular protein Cyclophilin A 
leading to its essential inclusion into HIV virions and, after cleavage, the CA protein forms the 
conical core of viral particles. [32-34]. Before cleavage, the NC-region of Gag recognizes and 
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binds the ψ-packaging signal of the HIV RNA genome for encapsidation into the virion [35,36]. 
After cleavage, NC remains in tight association the viral RNA via conserved basic residues 
within the viral core and upon release from the core NC stimulates reverse transcription and 
integration [37]. The uncleaved p6-region Gag binds the virally encoded accessory protein Vpr 
for encapsidation into the virion [38]. The p6-region also recruits cellular factors of the ESCRT 
machinery, such as Tsg101 and AIP1/ALIX, required for the efficient release of budding virions 
from the cell membrane [39-44].  The Env glycosylated polyprotein (gp160) of HIV-1 is 
expressed from a singly-spliced bicistronic mRNA and proteolytically processed by host furin 
protease to generate the surface (SU, gp120) and transmembrane (TM, gp41) subunits of the 
mature Env glycoprotein complex [45-47]. Mature Env exists as trimers on the surface and 
anchored in the envelope of the virion and is responsible for binding cellular CD4 
receptor/CCR5 or CXCR4 coreceptor and mediating viral entry into the host cell [48,49]. 
The enzymatic gene products are encoded by pol and translated as a Gag-Pol fusion-
protein precursor, p160, and are the major targets for available drugs. The pol gene includes the 
enzymes protease (PR, p11) reverse transcriptase (RT, p66/p51) and integrase (IN, p32). The 
expression of Gag-Pol is the result of a -1 ribosomal frame shift occurring at a UUUUUUA 
heptanucleotide site upstream a short stem loop near the 5’-end of gag [50]. Ribosomal pausing 
at the structured loop can allow infrequent, approximately 5 %, slippage on the poly-U tract 
resulting in the frame shift [51,52]. PR is a homodimer aspartyl protease and PR activity is 
required for cleavage of the Gag and Gag-Pol fusion-proteins described above [53-56].  RT is a 
heterodimer of p66 and p51, a product of PR cleavage of the C-terminal RNase H domain of 
p66, which has RNA-dependent and DNA-dependent DNA-polymerase activities [57-60]. 
During reverse transcription, RT produces a double-stranded DNA copy from the single-stranded 
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RNA genome. RT also has RNase H activity that degrades the RNA in a RNA/DNA hybrid 
duplex that allows the complementary strand of DNA to be polymerized [61]. IN is active as a 
dimer-of-dimers and is responsible for the biochemical reactions of 3'-processing and stand 
transfer leading to the stable integration of the reverse transcribed DNA proviral genome into the 
cellular DNA [62-64]. 
The regulatory gene products are encoded by tat and rev. The basal level of HIV 
transcriptional elongation is very low and is increased by the functions of the RNA binding 
protein trans-activator of transcription (Tat) [65-67]. Tat is expressed early from a fully-spliced 
mRNA transcript and functions by increasing the processive efficiency of RNA Polymerase II 
transcription [68]. In the nucleus, Tat binds to a structural element in the 5’ viral mRNAs called 
the trans-activating response element (TAR), where it recruits the serine kinase CDK9 and other 
cellular co-factors [69-72]. This complex results in the phosphorylation the carboxylterminal 
domain (CTD) of RNA polymerase II and promotes full-length transcription of the viral genome. 
The regulator of virion expression (Rev) is responsible for the transition from transcription of 
early, fully-spliced mRNA transcripts to late, unspliced variants. Typically, unspliced mRNA is 
restricted to the nucleus by the nuclear pore-associated proteins, Mlp1 and Pml39, the 
nucleoporin Nup60, the nuclear envelope protein Esc1, and the nucleoplasmic protein Pml1 [73-
76]. Rev binds a structural element found in unspliced viral mRNA called the Rev response 
element (RRE), inhibits splicing and escorts unspliced mRNA transcripts into the cellular 
cytoplasm for ribosomal translation [77-80]. This allows expression of the structural, enzymatic 
and accessory gene products, as well as transcription of the full-length viral genome for 
packaging [81,82].  
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The accessory gene products are encoded by nef, vif, vpr and vpu are not essential for 
infectivity in vitro, but are essential pleiotropic virulence factors in vivo. Nef is one of the first 
proteins expressed following infection and has several important functions. The most prominent 
function is the downregulation of cell surface expression levels of proteins such as CD4, subset 
of major histocompatibility complex class I molecules, mature major histocompatibility complex 
class II molecules, CD28, CD8, CXCR4, CCR5 and the transferrin receptor [83-91]. The effects 
of these changes are broad and range from increased viral release to blocked superinfection and 
immune evasion. Vif counteracts the cytosine-deaminase, APOBEC3G, restriction factor that 
causes C?U transitions on the minus-strand DNA during reverse transcription when the factor is 
incorporated into virions [92,93]. Vif targets APOBEC3G for polyubiquitylation and subsequent 
proteasomal degradation to circumvent hypermutation by recruiting an ubiquitin-ligase complex 
including the cellular proteins elongin B and C, cullin-5 (CUL5) and ring-box-1 (RBX1) [94-98]. 
Vpr supports infection of dividing and non-dividing cells through effects including nuclear 
localization, G2 cell cycle arrest, apoptosis, and transactivation of host and viral genes [99-110]. 
CD4 in the endoplasmic reticulum binds and blocks traffic of Env gp120, Vpu targets the 
degradation of CD4 here and restores virion production by recruiting the cullin1-Skp1 ubiquitin-
ligase complex for polyubiquitylation and subsequent proteasomal degradation [111]. Vpu also 
counteracts the type 1 interferon induced tetherin (BST-2) from blocking virion release from the 
cell membrane by an unknown mechanism [112-115].  
1.1.2 Viral replication 
The replication cycle, Figure 3, of HIV can be outlined in an ordered sequence of events 
beginning with circulating virion in the blood or lymphatic systems. The initial event in viral 
 7 
entry requires the recognition and high affinity binding of gp120 to the target cell receptor CD4 
present on a subset of macrophages and T-lymphocytes [116,117]. CD4 recognition alone is not 
sufficient to induce Env-mediated entry and gp120 binding to a coreceptor is also required. Two 
cellular G-protein coupled receptors are important HIV coreceptors: the β-chemokine receptor 
CCR5 and the α-chemokine receptor CXCR4 [118,119]. Transmitted viral Env is typically able 
to recognize only CCR5, called R5 isolates, that is present on macrophages. However, mutations 
acquired during repeated replication cycles eventually convert Env coreceptor recognition to 
CXCR4, called X4 isolates, that is present on T-cell lines [120]. In either case, the complex 
formed by Env, CD4 and a coreceptor triggers a conformational change in the Env gp41 subunit 
resulting in membrane fusion [121,122].  
The fusion of lipid bilayers releases the viral core into the cytoplasm. The core partially 
dissembles as CA diffuses away leading to the formation of a reverse transcription complex 
(RTC) containing MA, NC, RT, IN, Vpr and genomic RNA [123-125]. The conversion of viral 
RNA to a DNA intermediate is a defining characteristic of retroviruses and is discussed in detail 
below. Complete synthesis of the cDNA genome results in the formation of the pre-integration 
complex (PIC) containing the viral components of the RTC and additional cellular factors 
including, barrier to auto-integration factor (BAF), high mobility group protein HMGA, Ku and 
LEDGF/p75 [126-130]. The PIC is actively transported into the cell nucleus where the cDNA is 
stably integrated into the host genome by the activities of IN as a provirus. Here, the provirus can 
be transcribed or enter latency [131]. Long-lived, latently infected cells likely become the so-
called viral reservoir that has made the cure for HIV infection elusive. 
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 Figure 3: Replication cycle of HIV 
Under favorable conditions RNA Pol II can transcribe the proviral DNA, but with poor 
processivity using the long terminal repeat (LTR) as the site of initiation [132,133]. Rarely, full-
length transcripts are produced and fully spliced to express viral Tat, Rev and Nef. As described 
above, the activities of Tat greatly enhance the transcription of full-length transcripts and Rev 
allows the nuclear export of partially spliced transcripts for the expression of Env, Vif, Vpu and 
Vpr or unspliced transcripts for the expression of Gag and Gag-Pol. 
The expression of the full complement of viral proteins leads to the virion assembly 
process. Env gp120 is synthesized in the rough endoplasmic reticulum, trafficked through the 
Golgi apparatus where it is glycosylated and cleaved by furin protease into gp120 and gp41 
before being transported to the cell surface via the secretory pathway [134-136]. The expression 
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of the polyprotein Gag is sufficient for the assembly of viral like particles at the cell membrane 
and budding from the cell [137]. However, for infectious virion assembly, the Gag NC domain 
must encapsidate two copies of the viral genome, co-package some Gag-Pol and essential viral 
and cell factors. 
Release of the immature viral particle from the cell membrane, or budding, requires the 
recruitment of cellular endosomal sorting complex required for transport (ESCRT) machinery 
[44,138-142]. These proteins interact with the Pro-rich late domains of the p6 domain of Gag and 
function to pinch off the viral membrane from the cell membrane. After, or during, budding, 
viral Pro cleaves the Gag and Gag-Pol polyproteins at nine sites to release the mature structural 
and enzymatic proteins. The cleavage of MA-CA triggers core assembly into the classic cone 
shape observed in mature virions [143-145]. The virus is released into the extracellular space in 
order to circulate and infect a new cell.  Despite the large quantities of circulating virus often 
observed, many virions are non-infectious because of defects and cannot complete the necessary 
steps for infection. 
1.2 HIV-1 REVERSE TRANSCRIPTASE 
The viral enzyme RT mediates the conversion of the HIV genome during the process of reverse 
transcription. HIV RT is a multifunctional enzyme with RNA-dependent and DNA-dependent 
DNA-polymerase and RNase H activities [57-60]. This section details the structure of HIV-1 RT 
and the individual steps and molecular mechanisms of HIV-1 DNA synthesis. 
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1.2.1 Structure of HIV-1 reverse transcriptase 
The HIV-1 RT gene encodes full-length p66, however the active enzyme is a heterodimer of p66 
and p51, Figure 4 [146-148]. The p66 contains three domains: the polymerase (residues 1-318), 
connection (319-426) and RNase H (427-565). The polymerase domain is configured like that of 
the Klenow fragment of Escherichia coli DNA polymerase I in a the shape of a ‘right hand’ with 
fingers, palm and thumb subdomains [149]. The active site of the polymerase domain sits in the 
palm subdomain and contains the catalytic triad aspartate residues (D110, D185, D186) and is 
the site of RNA-dependent and DNA-dependent DNA polymerization. The connection domain 
lacks catalytic activity and the C-terminal RNase H domain is structurally similar to RNase H of 
Escherichia coli [150,151] and Thermus thermophilus [152] and is responsible for the digestion 
of the RNA component of a RNA/DNA hybrid. The p51 subunit is the product of PR C-terminal 
cleavage of p66 and lacks the RNase H domain [153]. The domains of p66 and p51 are folded in 
similar dimensions, but the spatial arrangement in each subunit varies. The p66 is described as 
being ‘open’ with a cleft for binding the template/primer with the 5’end of the primer sitting at 
the polymerase active site, while p55 is ‘closed’ and acts as a structural scaffold without catalytic 
activity [154]. 
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 Figure 4: Structure of the p66/p51 HIV-1 RT heterodimer 
The subunit p66 is colored by domain polymerase (green, residues 1-318), connection (blue, 
residues 319-426) and RNase H (yellow, residues 427-565), the p51 subunit is colored grey, the 
bound RNA/DNA Template/Primer is in light and dark red, respectively, and a bound dNTP is 
siting in the polymerase active site. Rendered with coordinates PDB: 1HYS [155] using The 
PyMOL Molecular Graphics System, Version 1.5.0.4 Schrödinger, LLC. 
1.2.2 Process of reverse transcription 
The conversion of the HIV RNA genome to a DNA intermediate follows a concerted series of 
steps, Figure 5. The multifunctional HIV-1 RT completes all of the steps of reverse transcription, 
although other viral and cell cofactors are present in the reverse transcriptase complex (RTC). 
1. RNA-dependent DNA-polymerization is initiated using a bound molecule of cellular 
tRNALys3 hybridized to the genome primer-binding site (pbs) and polymerization 
continues to the 5’ terminus creating a RNA/DNA hybrid [28,156,157].  
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2. RNase H degradation of the hybrid RNA produces the minus-strand strong-stop DNA (-
sssDNA) [158].  
3. The -sssDNA relocates to the 3’-end of the genome using regions of homology (R) in a 
process called the first strand transfer [159].  
4. The polymerization of the minus-strand continues using the -sssDNA as a primer.  
5. RNase H degrades the genome during minus-strand synthesis, but leaves two purine-rich 
segments, the 3’- and central-polypurine tracts (PPT) [160]. Each RNA PPT is used as a 
primer for plus-strand synthesis with the minus-strand DNA and 18 nucleotides of the 
tRNA as a template, DNA-dependent DNA polymerization.  
6. RNase H degradation of the tRNA allows the second strand transfer mediated through 
homology of the pbs [161]. Both segments of RNA PPT are removed by RNase H 
activity. 
7. DNA synthesis of both the minus-strand and plus-strand from the central PPT primer 
continue to complete their respective LTRs. DNA synthesis of the plus-strand from the 
central PPT primer continues and displaces the plus-strand from the central PPT primer 
by approximately 100 nucleotides until the central termination signal (CTS).  This 
displacement creates a discontinuous plus-strand with a central DNA flap that is 
important for viral replication [162,163]. 
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 Figure 5: Reverse transcription of the HIV-1 genome 
The synthesis of double-stranded HIV-1 DNA from the viral RNA genome is mediated by viral 
reverse transcriptase. RNA and DNA are indicated in in red and green, respectively, the 
tRNALys3 primer is indicated in blue, RNase H degradation is indicated by dashed lines. PBS, 
primer binding site; cPPT, central polypurine tract; CTS, central termination signal; PPT, 
polypurine tract. 
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1.2.3 Mechanism of DNA polymerization by HIV-1 RT 
HIV-1 RT is multifunctional and has both RNA-dependent and DNA-dependent DNA 
polymerase activities. The polymerase active site is located in the middle of the palm, fingers, 
and thumb subdomains of the p66 subunit. The palm subdomain positions the primer terminus in 
the correct orientation for the nucleophilic attack on an incoming dNTP [164]. DNA synthesis 
follows an ordered-sequential bi bi kinetic mechanism, Figure 6 [58,165-167]. First, RT binds 
the template/primer (T/Pn) at the primer-binding site (Figure 6, step 1). This binary complex is 
stabilized by a change of the conformation of the p66 thumb from “closed” to “open” [168,169]. 
Then, the dNTP binds at the nucleotide-binding site to form an RT:T/Pn:dNTP ternary complex 
(Figure 6, step 2). Afterwards, a rate-limiting conformational change of the fingers traps the 
bound dNTP and aligns the 3′-OH of the primer and the α-phosphate of the dNTP to stabilize the 
transition state at the polymerase active site [170-172]. Then, RT catalyzes the formation of a 
phosphodiester bond between the primer 3′-OH and the dNMP to extend the primer strand by a 
single nucleotide and create a RT:T/Pn+1:PPi ternary complex (Figure 6, step 3). After the release 
of the pyrophosphate molecule, translocation of RT along the nascent elongated DNA primer 
frees the nucleotide-binding site for the next incoming dNTP for processive synthesis (Figure 6, 
step 4) or RT can dissociate from the complex and must rebind the same or different T/P for 
distributive synthesis to continue (Figure 6, step 5). 
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 Figure 6: Kinetic mechanism of HIV-1 RT DNA synthesis 
HIV-1 RT polymerization in the absence of inhibitor: (1) T/P binds to the RT enzyme; (2) dNTP 
binds to the nucleotide binding site of the RT·T/P complex; (3) a conformational change and 
catalysis must occur before (4) processive binding of the next dNTP or (5) enzyme dissociation. 
ATP-mediated excision is the ability of HIV-1 RT to remove the 3’-terminal nucleotide from the 
nascent extended primer (6). 
 
During DNA polymerization, the conserved residues Asp110, Asp185 and Asp186 
coordinate two Mg2+ cations, A and B, Figure 7. Cation A activates the 3’-hydroxyl group of the 
primer by lowering the pKa and coordinates the nucleophilic alkoxide [173]. Both cations 
stabilize the hypothetical pentacovalent α-phosphorus transition state. Additionally, cation B 
coordinates the β- and γ-phosphates to stabilize the negative charge of the leaving 
pyrophosphate. This general two metal ion-catalyzed mechanism is a common feature of 
polymerase and nuclease enzymes across a wide range of viral, bacterial and metazoan species 
[173-175].   
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 Figure 7: Molecular mechanism of catalytic DNA polymerization by HIV-1 RT 
HIV-1 RT uses a two metal cation-catalyzed DNA polymerase mechanism. A conserved 
aspartate triad in the polymerase active site coordinates the Mg2+ cations, A and B. Cation A 
activates the primer’s 3’-OH for attack on the α-phosphate of the bound dNTP. Both cations 
stabilize the pentacovalent transition state. Cation B also chelates the dNTP β- and γ-phosphates 
and stabilizes negative charge of the leaving pyrophosphate  
1.2.4 Mechanism of RNase H cleavage by HIV-1 RT 
RT RNase H activity is able to selectively degrade the RNA portion of a RNA:DNA hybrid and 
to remove the priming tRNA and PPT during the phases of reverse transcription. The RNase H 
domain is located at C-terminus of the p66 subunit, 60 Å from polymerase active site or a 
distance of 18 nucleotides of a RNA:DNA hybrid from the RT nucleotide binding site [176]. The 
RNase H active site contains a conserved DDE motif containing the residues D443, E478, D498, 
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and D549, which coordinate two Mg2+ cations [177]. RNase H activity is essential and mutations 
in any of the D443, D498, or E478 residues abolish RNase H activity and result in replication 
incompetent virus [178,179]. The RNase H domain catalyzes a phosphoryl transfer by 
nucleophilic substitution reactions on the phosphodiester backbone of the RNA template, Figure 
8. The molecular mechanism is proposed to occur through the assisted deprotonation of a water 
molecule (A) to produce a nucleophilic hydroxide ion that attacks the scissile phosphate group in 
coordination with Mg2+ cations [180]. The nucleophilic attack requires the simultaneous 
destruction of the weak P-O π-bond and results in a pentavalent transition state around the 
phosphorus. The transition state resolves after the reformation of the P-O π-bond and movement 
of electrons to the 3’-hydroxyl of the adjacent ribose sugar. This results in the cleavage of the 
biopolymer into two separate RNA molecules, one with a new 3’-end and one with a new 5’-end. 
The specificity of RNase H cleavage for the RNA portion of the RNA:DNA hybrid is 
dependent on the minor groove width and its interaction with the RNase H primer grip region, a 
group of residues of p66 and p51 subunits that interact with the hybrid phosphate backbones 
[164]. The minor groove width of a RNA:DNA is intermediate between the A- and B-forms of 
other nucleic acids with a variable distance  between 9 to 10 Å. The activity of HIV-1 RNase H 
is less efficient for hybrids with narrower widths, like the PPTs with a width of 7 Å due to the 
presence of poly-A-tracts [155,181-185]. This preserves the PPT regions to act as primers during 
the initiation of plus-strand synthesis during reverse transcription, but ultimately allows for their 
removal after the second strand transfer reaction. 
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 Figure 8: Molecular mechanism of catalytic RNase H activity by HIV-1 RT 
HIV-1 RT RNase H activity selectively degrades the RNA portion of a RNA:DNA hybrid. In the 
RNase H active site of p66, water A molecule is activated by lowered pKa from coordinated 
Mg2+ A. The resulting hydroxide ion is directed to the scissile phosphate in the RNA backbone. 
The Mg2+ B stabilizes the phospholeaving group after relaxation of the pentavalent transition 
state through the breaking and reformation of the phosphor-carbonyl π-bond. The DNA portion 
of the double-stranded RNA:DNA hybrid substrate has been omitted for clarity. 
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RNase H catalysis can occur with three different types of cleavage modes: polymerase-
dependent DNA 3′-end directed cleavage, polymerase-independent RNA 5′-end directed 
cleavage and internal cleavage, Figure 9. The DNA 3′-end directed cleavage acts during 
processive minus-strand DNA synthesis, when the RNase H cleaves the RNA in a position based 
on the binding of the polymerase active site to the 3′-end of the DNA primer at a rate of one 
cleavage per 100-200 nucleotides incorporated [155,168,172,186-188]. The RNA 5′-end directed 
cleavage acts during the removal of the tRNALys3 primer, PPT and cPPT tract during plus-strand 
DNA synthesis when the polymerase active site binds the RNA recessed 5′-end and the RNase H 
cleaves the RNA strand 13–19 nucleotides away from its 5′-end [185,187,189-192]. The internal 
cleavage is essential to remove the left over RNA during plus-strand synthesis since the RNase H 
cleavage is slower than DNA synthesis and any non-polymerizing RTs molecules can bind to the 
hybrid and degrade the RNA segment by a polymerase-independent mode [155,193]. 
 
Figure 9: Modes of HIV-1 RT RNase H cleavage 
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1.3 ANTIRETROVIRAL THERAPY 
The discovery of HIV was preceded by the clinical appearance of AIDS. HIV primarily infects 
CD4+ T cells and ultimately kills these cells during the virion replication cycle. The late stage of 
HIV infection results in AIDS when the depleted CD4+ cell count falls below 200 cells/μl and 
renders the person susceptible to opportunistic infections and malignancies that are normally 
controlled by a healthy immune system. The basis of antiretroviral therapy is that the protection 
of uninfected cells by blocking iterative cycles of viral infection permits restoration of immune 
function, or prevents further loss of, immune function to delay the onset of AIDS.  
To date, there are 36 FDA-approved antiretroviral products, formulated either singly or in 
combination, to treat patients infected with HIV-1 [194]. Most are oral medicines, administered 
on convenient schedules in order to increase regimen adherence. Several products have been 
specially formulated as fixed-dose, generic-drug combinations for ease and affordability in 
resource-poor nations. Antiretroviral therapy can suppress viral replication for decades and 
dramatically increase the life expectancy of HIV-infected individuals. However, HIV is a 
lifelong, chronic infection with no defined cure. The therapy is compromised by non-adherence, 
adverse side effects and drug interactions among antiretrovirals and other medications. Each of 
these can lead to reduced plasma serum drug concentrations to suboptimal levels that result in 
the virologic failure and subsequent evolution of viral drug resistance. 
1.3.1 History of antiretroviral therapy 
During the first decade of the epidemic, the treatment of HIV largely consisted of prophylaxis 
against and management of common opportunistic infections and AIDS-related illnesses. The 
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first HIV-specific drug, 3’-azido-2’,3’-dideoxythymidine (AZT), was discovered in the early 
1990s and was administered as a single drug, monotherapy, but drug-resistance treatment failure 
was common [195-200]. The discovery of additional antiviral compounds in the mid-1990s 
allowed the standard of care to advance by including combinations of drugs to be administered 
together in a highly active antiretroviral therapy (HAART) [201-203]. These “cocktails” 
dramatically lengthened the delay of the onset of AIDS, however, early regimens consisted of 
complex dosing schedules, severe side-effects and heavy pill burdens with up to 20 pills/day. 
Improved HAART regimens were developed and continue to be enhanced to increase therapeutic 
efficacy and reduce the negative effects of the drugs. The most important aspect of combination 
therapy is the prevention of drug resistance evolution by using three antiretroviral agents directed 
against at least two distinct targets. Modern HAART dramatically suppresses viral replication 
and reduces the plasma viral load to below <50 RNA copies/mL, the limit of detection for 
clinical assays, and often results in a significant increase of circulating CD4+ T-lymphocytes 
[204-206].  
In 2012, HIV-1 treatment guidelines for resource-rich countries recommend the initiation 
of HAART with three fully active antiretroviral agents for all infected adults and adolescents [6]. 
Early initiation of treatment reduces the risk of disease progression and transmission of HIV. 
HIV drug resistance mutations have been found in both patients failing therapy and in 
therapy-naïve patients infected with transmitted, drug-resistant viruses. Most patients, including 
those with a history of failure, can be treated successfully because of the quantity of agents and 
distinct targets of antiretroviral drugs currently available. However, the virus continues to evolve 
drug resistance to current therapies, so new HIV-1 treatments will always be needed.  
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1.3.1.1 Reverse transcriptase inhibitors 
Reverse transcription is the most targeted step for antiretrovirals approved by the FDA. There are 
two main classes of reverse transcriptase inhibitors called nucleoside reverse transcriptase 
inhibitors (NRTI) and non-nucleoside reverse transcriptase inhibitors (NNRTI). In addition, a 
non-nucleoside pyrophosphate analog called foscarnet also inhibits RT, but is rarely utilized 
because it is associated with nephrotoxicity and has limited bioavailability [207-210]. RNase H 
activity is another promising target for inhibition, but no drugs have been approved for this to 
date. 
There are eight FDA-approved NRTIs currently available, that structurally resemble both 
purine, Figure 10A, and pyrimidine, Figure 10B, analogs of naturally occurring nucleosides. 
Purine nucleoside analogs include the adenine analogs 2′,3′-dideoxyinosine (didanosine, ddI) and 
([[(2R)-1-(6-amino-9H-purin-9-yl)propan-2-yl]oxy]methyl)phosphonic acid (tenofovir, TNV) 
and the guanosine analog (1S-4R)-4-[2-amino-6-(cyclopropylamino)-9H-purin-9yl]-2-
cyclopentane-I-methanol (abacavir, ABC). Pyrimidine nucleoside analogs include the cytosine 
analogs such as 2′,3′-dideoxycytidine (zalcitabine, ddC), (-)-β-L-2′,3′-dideoxy-3′-thiacytidine 
(lamivudine, 3TC), and (-)-β-L-2′,3′-dideoxy-3′-thia-5-fluorocytidine (emtricitabine, FTC) and 
the thymidine analogs such as 3′-azido-2′,3′-dideoxythymidine (zidovudine, AZT), and 2′,3′-
didehydro-2′,3′-dideoxythymidine (stavudine, d4T).  
The general structure of all current NRTI includes the distinct lack of a 3′-hydroxyl group 
at the sugar moiety. While modified sugars structures are common, most active, metabolized 
compounds have base structures that remain identical to the natural base structures, with the 
exception of FTC. The HIV-1 RT still binds and utilizes these modified compounds and allows 
them to be effective inhibitors of the virus. 
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Figure 10: Structures of natural nucleoside & nucleoside analog reverse transcriptase inhibitors 
Structures of all currently FDA-approved purine (A) and pyrimidine (B) analogs 
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All NRTI are administered as inactive parent “pro-drugs” that must be metabolized by 
cellular enzymes into the active compounds for the inhibition of RT, Figure 11. The compounds 
must be transported into cells by either passive diffusion or carrier-mediated transport after they 
enter the bloodstream to be metabolized [211].  A myriad of cellular phosphotransferases and 
nucleoside/tide kinases are required to convert the inactive drugs into deoxynucleoside-
triphosphates that can then compete with natural nucleotides for binding in the N-site of RT 
during polymerization [212]. Incorporation of an NRTI-MP into the nascent viral DNA chain by 
RT results in termination of DNA synthesis because there is no 3’-hydroxyl at the primer 
terminus for additional nucleotides to be added, Figure 11. 
Figure 11: Intracellular phosphorylation of 3’-azido-2’,3’-ddG and chain termination 
The putative phosphotransferases and nucleoside/tide kinases responsible for the anabolic 
metabolism of 3’-azido-2’,3’-ddG-triphosphate are not known, but produce the observed mono-, 
di- and triphosphate metabolites. Each metabolite has been identified in previous studies and the 
incorporation of 3’-azido-2’,3’-ddG-monophosphate by RT terminates further DNA synthesis 
because there is no 3’-hydroxyl at the primer terminus. 
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1.3.1.2 Didanosine (ddI) 
ddI is a 2’,3’-dideoxy-structural analog of the natural purine nucleoside 2’-deoxyadenosine (dA). 
Cytosolic 5'-nucleotidase phosphorylates ddI to didanosine-monophosphate (ddI-MP) using 
inosine monophosphate or guanosine monophosphate as phosphate donors [213]. A reversible 
amination by adenylosuccinate synthetase and adenylosuccinate lyase converts the hypoxanthine 
base of ddI-MP to an adenine base to produce ddA-MP [214-216]. Additionally, 5'-adenosine 
monophosphate-activated protein kinase phosphorylates ddA-MP to ddA-DP and nucleotide 
diphosphate kinase phosphorylates ddA-DP to the active metabolite ddA-TP.  
Although 2’,3’-dideoxyadenosine (ddA) shows antiviral activity in vitro, the compound is 
acid labile and in clinical practice is converted by the low pH of the stomach secretions into free 
adenine [217]. Excess adenine is oxidized by xanthine dehydrogenase to 2,8-dihydroxyadenine, 
which is highly insoluble and its accumulation in the kidney can lead to crystalluria and 
concomitant nephrotoxicity [218]. This metabolic pathway is bypassed by the administration of 
acid-stable ddI instead of ddA. However, regimens including ddI are increasingly rare because it 
has been correlated with nucleoside analogue-associated peripheral neuropathy [219-221]. 
Treatment with ddI usually selects for the mutation L74V in reverse transcriptase [222]. 
This residue in p66 is located in the flexible finger subdomain of the β2-β3 loop and interacts 
with the template nucleotide that is base-paired to the incoming dNTP or NRTI-TP. In addition, 
L74 is proximal to residues Q151 and R72 that interact directly with the bound dNTP or NRTI-
TP [172]. It is likely that the L74V mutation changes the packing rearrangements of the NRTI-
TP to decrease NRTI-TP binding affinity or catalysis, while maintaining the ability to 
incorporate natural dNTP molecules. Additionally, the mutation M184V confers 2- to 5-fold ddI 
resistance, but only occurs in approximately ten percent of patients receiving ddI [223]. Other 
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mutations not selected during ddI monotherapy have also have been determined to confer 
resistance phenotypes. The mutation K65R causes 3- to 5-fold resistance and V75T causes about 
5-fold ddI resistance in vitro [223-225]. 
1.3.1.3 Tenofovir (TNV) 
TNV is an acyclic-structural nucleoside-phosphonate analog of the natural nucleotide 2’-
deoxyadenosine-5’-monophosphate [226]. TNV is administered as the fumaric acid salt of the 
bis-isopropoxycarbonyloxymethyl ester derivative (9-[(R)-2- 
[[bis[[(isopropoxycarbonyl)oxy]methoxy]phosphinyl]methoxy]propyl]adenine fumarate) of 
tenofovir (TDF) to increase the oral bioavailability [227]. In vivo, cellular carboxylesterases and 
phosphodiesterases quickly metabolize TDF into the nucleotide phosphonate TNV for additional 
phosphorylation [228,229]. The phosphonate carbon-phosphorus bond is very stable and 
bypasses the rate limiting initial phosphorylation towards the active drug TNV-diphosphate. 
Treatment with TNV usually selects for the mutation K65R in reverse transcriptase [230-
232]. This residue in p66 is located in the finger subdomain in the β3-β4 loop and the ε-amino 
group of K65 interacts with the γ-phosphate of the incoming dNTP or NRTI-TP. The spatial 
arrangements of the mutated residue 65R may alter the binding position of the dNTP and 
decreases the efficiency of incorporation by approximately three-fold [233]. However, reduced 
tenofovir susceptibility is also observed in patients with the AZT-resistance mutations at 
positions M41L and L210W [234].  
1.3.1.4 Abacavir (ABC) 
ABC is a carbocyclic-structural analog of the natural nucleoside 2’-deoxyguanosine [235,236]. 
ABC is metabolized in multiple steps to produce the active inhibitor compound guanosine-
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triphosphate analogue (-)-carbovir-triphosphate (CBV-TP) [237-239]. CBV is not 
phosphorylated, while ABC is phosphorylated by adenosine phosphotransferase to ABC-
monophosphate. The 6-aminocyclopropyl group of ABC-monophosphate is removed by 
cytosolic deaminase to produce CBV-monophosphate. CBV-diphosphate is produced by 
guanidinylate monophosphate kinase. Several cellular enzymes including 5’-nucleotide 
diphosphate kinase, pyruvate kinase, or creatine kinase can then produce the active inhibitor 
CBV-triphosphate. 
In vitro selection experiments have identified that the mutations K65R, L74V, Y115F and 
M184V accumulate in RT in the presence of ABC. Furthermore, combinations of these 
mutations are required for ABC resistance with at least two or three mutations required to 
produce a 10-fold reduction in susceptibility compared to WT virus [240]. ABC monotherapy in 
vivo closely resembles the results found in cell culture [241,242]. The residues L74 and K65 are 
located within the finger subdomain, away from the active site and are involved with template-
primer binding. L74 interacts with the incoming nucleotide through hydrogen bonding and is 
required for processivity and wild-type levels of replication fitness in cell culture [172,243]. The 
residue Y115 of p66 is in the nucleotide-binding pocket near the active site Asp185 and the 
neighboring M184 residue.  The 4-hydroxyl group of Y155 is a steric gate that blocks the 2’-
hydroxyl of ribonucleotides such that RT can only bind and incorporate dNTPs as a DNA 
polymerase [244,245]. The β-branched functional group of M184V can interact with the sugar 
structure of a bound dNTP and can sterically hinder the binding of non-natural substrates [172]. 
1.3.1.5 Zalcitabine (ddC) 
ddC is a 2’,3’-dideoxyribose-structural analog of the natural nucleoside 2’-deoxycytidine [246]. 
Numerous large-scale clinical trials have established that ddC-containing regimens are less 
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effective than other analogous combinations of NRTIs [247-251]. Furthermore, ddC is associated 
with two toxic effects: a dose and duration-related peripheral neuropathy and characteristic 
ulcerations of mucous membranes [252,253]. Therefore, ddC is largely is considered as obsolete 
if other NRTIs are available. 
The major ddC resistance mutation selected in vivo within RT is T69D and results in a 5-
fold decrease in susceptibility [254]. Rarely, selection of K65R provides a 4- to 10-fold decrease 
in susceptibility, or V75T provides a 19-fold decrease in susceptibility [224,225,255]. 
1.3.1.6 Lamividine (3TC) 
3TC is an oxathiolane ring containing (-)-L-enantiomeric-structural analog of the natural 
nucleoside of 2’-deoxycytidine that was first tested as a component in a mixture of unresolved 
racemates of β-DL-(±)-2’,3’-dideoxy-3’-thiacytidine (BCH-189) with an EC50 of 0.06 μM in 
PBMC and a CC50 of 52.6 μM in CEM cells [256-258]. Separation of the optical isomers by high 
performance HPLC showed that the β-(-) isomer was both a potent (EC50 of 0.002 μM in PBMC) 
and  non-cytotoxic (CC50 of >100 μM in CEM cells), while the β-(-) isomer was both non-potent 
(EC50 of 0.2 μM in PBMC) and  cytotoxic (CC50 of 2.7 μM in CEM cells) [257]. 3TC is 
phosphorylated to the 5'-mono-, di- and triphosphate derivatives by deoxycytidine kinase, 
deoxycytidine monophosphate kinase, and 5’-nucleoside diphosphate kinase, respectively [259-
261]. 
Treatment with 3TC selects for the mutation M184V in RT p66 in vitro and in vivo 
[262,263]. The β-branched amino acid valine sterically hinders the binding of 3TC in the active 
site by interacting with the large sulfur atom of the oxathiolane ring [264,265]. Natural dNTPs 
can still bind in the presence of M184V and be incorporated. Interestingly, the presence M184V 
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makes RT more susceptible to AZT by reducing the removal of chain-terminating nucleotides by 
ATP-mediated phosphorolysis [266]. 
1.3.1.7 Emtriciabine (FTC) 
FTC is the 5-fluorinated-structural analog of 3TC and is also an oxathiolane ring containing (-)-
L-enantiomeric analog of the natural nucleoside 2’-deoxycytidine. The cellular metabolism of 
FTC follows the same path as 3TC where FTC is phosphorylated to the 5'-mono-, di- and 
triphosphate derivatives by deoxycytidine kinase, deoxycytidine monophosphate kinase, and 5’-
nucleoside diphosphate kinase, respectively [259-261,267]. The binding affinity of FTC to RT is 
higher than 3TC due to the additional stabilizing hydrogen-bond formed between the 5-Fluoro 
group and residue R72 in RT, which may account for the increased potency and delay of selected 
resistance [268,269]. 
Resistance to FTC occurs through the RT mutation M184V via a mechanism similar to 
3TC, however selected resistance was 10-fold less for FTC over 3TC under identical in vitro 
conditions [262]. 
1.3.1.8 Stavudine (d4T) 
d4T is a 2’,3’-didehydro-2’,3’-dideoxy-structural analog of the natural nucleoside 2’-
deoxythymidine [270]. d4T is phosphorylated to the 5'-mono-, di- and triphosphate derivatives 
by thymidine kinase, thymidylate kinase, and 5’-nucleoside diphosphate kinase, respectively 
[271-274]. In 2009, the World Health Organization recommended that all countries phase out the 
use of d4T because of its long-term, irreversible side effects. d4T-5’-triphosphate inhibits 
mitochondrial DNA polymerase γ that can lead to cumulative toxicity resulting in lipoatrophy, 
peripheral neuropathy, lactic acidosis, or pancreatitis [275,276]. 
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Resistance to d4T has an interesting phenomenon in which resistance selected in vitro is 
markedly different than what has been observed in vivo. Cell culture studies found that K65R 
was selected and conferred approximately 15-fold resistance to d4T, while virus isolated from 
patients failing d4T regimens did not have K65R and developed the canonical AZT-resistance 
mutations thymidine analogue mutations (TAMs), discussed below [277,278]. Additionally, the 
mutation V75T has appeared in clinical isolates from patients treated with this compound and 
confers a 5-fold resistance over WT as well as most mutations conferring AZT-resistance 
[225,279]. 
1.3.1.9 Zidovudine (AZT, ZDV) 
AZT is a 3’-azido-structural analog of the natural nucleoside 2’-deoxythymidine and was the 
first discovered anti-HIV compound in 1987 [195-200,280]. AZT is metabolized through the 
same pathway as d4T and is phosphorylated to the 5'-mono-, di- and triphosphate derivatives by 
thymidine kinase, thymidylate kinase, and 5’-nucleoside diphosphate kinase, respectively 
[272,281-283]. 
The most common mutations developing during AZT treatment are the well-studied 
TAMs. These mutations accumulate in a stepwise manner along two distinct pathways, defined 
as TAM1 (including mutations M41L, L210W and T215Y) and TAM2 (including mutations 
D67N, K70R and K219E/Q) [199,200,284,285]. High-level resistance requires the accumulation 
of multiple TAMs and can result in over 16,000-fold resistance [286]. At least two NRTI 
mutations (L74V and M184V) and two NNRTI mutations (L100I and Y181C) partially reverse 
AZT resistance mediated by TAMs [223,287]. The mechanism through which the 184V mutation 
can resensitize viruses to AZT is attributable to the finding that 184V-containing enzymes have 
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reduced rates of phosphorolysis, however this effect may be overcome by a further accumulation 
of TAMs [266]. 
1.3.1.10 Non-nucleoside reverse transcriptase inhibitors (NNRTIs) 
NNRTIs inhibit HIV-1 RT by non-competitive binding and allosteric induction of a hydrophobic 
pocket near the polymerase active site [288,289]. The binding of NNRTIs cause the p66 thumb 
subdomain to become hyperextended because it stimulates rotations of the p66 amino acid 
residues Y181 and Y188 that in turn alters the conformation of the dNTP-binding site and 
reduces the DNA polymerase activity of RT [290]. The induced NNRTI-binding pocket consists 
of contains five aromatic (Y181, Y188, F227, W229 and Y232), six hydrophobic (P59, L100, 
V106, V179, L234 and P236) and five hydrophilic (K101, K103, S105, D132 and E224) amino 
acids that belong to the p66 subunit and additional two amino acids (I135 and E138) that belong 
to the p51 subunit. Currently there are five FDA-approved NNRTIs: efavirenz (EFV), nevirapine 
(NVP), delavirdine (DLV), etravirine (ETV) and rilpivirine (RPV), Figure 12. 
NNRTI resistance results from amino acid substitutions in the NNRTI-binding pocket of 
RT that abrogate binding affinity [289]. However, K103N and Y181C are the most common 
NNRTI mutations selected during failing regimens [291-296]. Most NNRTI mutations generate 
some degree of cross-resistance with different NNRTIs, especially when multiple mutations are 
selected [297]. Nevertheless, the DLV resistance mutation P236L also induces hypersensitivity 
to other NNRTIs [298]. 
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 Figure 12: Structures of non-nucleoside reverse transcriptase inhibitors 
All NNRTIs bind to RT in the same hydrophobic pocket, but contact different residues within the 
site. The first generation NNRTIs (including EFV, NVP and DLV) consist of butterfly-like 
structures with hydrophilic centers attached to two aromatic rings representing the wings. Second 
generation NNRTIs (including ETV and RPV) are diarylpyrimidines and consist of horseshoe-
like structures with a central polar pyrimidine rings and two lateral hydrophobic wing-moieties. 
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1.3.1.11 Protease inhibitors (PIs) 
The proteolytic cleavage of the gag and gag-pol polyprotein precursors into mature 
enzymes and structural proteins by HIV-1 PR is critical for virion maturation [53-56]. HIV PIs 
are compounds that competitively inhibit the action of the viral PR. These drugs prevent the 
maturation of HIV particles into their infectious form. Ten PIs are currently FDA-approved:  
saquinavir, ritonavir, indinavir, nelfinavir, amprenavir (no longer marketed), lopinavir, 
fosamprenavir, atazanavir, tipranavir and darunavir, Figure 13. Most PIs are prescribed with low 
dose of ritonavir that acts as an inhibitor of cytochrome P450-3A4 to reduce PI metabolism and 
extend PI serum half-life [299]. 
All approved PIs, with the exception of tipranavir, act as competitive peptidomimetic 
inhibitors that mimic the transition states of the enzyme’s natural substrates. The peptidomimetic 
inhibitors contain a hydroxyethylene core that is an uncleavable analog of a peptide bond [300-
307]. However, the non-peptidomimetic inhibitor tipranavir contains a 5,6-dihydro-4-hydroxy-2-
pyrone ring as a central scaffold [308]. There have been many mutations associated with PI-
resistance and cross-resistance is frequently observed between PIs due to their similar structures 
and mechanisms of inhibition [309]. HIV-1 develops PI-resistance through a sequential pathway 
by (1) selection of major resistance mutations in the PR gene, (2) acquisition of minor 
compensatory PR mutations and (3) development of mutations in the eight major cleavage sites 
of the gag and gag-pol polyprotein precursors that are better substrates for the mutant PI-resistant 
PR [310-312]. The major resistance mutations usually develop near the PR active site including 
residues involved in substrate binding. However, these changes usually coincide with a less 
active PR and results in decreased viral fitness that is compensated for by the accumulation of 
 34 
the minor mutations over time. The mutations located within PR cleavage sites also function to 
compensate for the altered activities of the mutant PR.  
 
Figure 13: Structures of protease inhibitors 
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1.3.1.12 Integrase strand transfer inhibitors (InSTIs)  
Strand transfer is a Mg2+-dependent trans-esterification reaction mediated by HIV-1 IN that 
directs the nucleophilic attack of the two newly processed viral genome 3´-DNA ends on the 
backbone of the host target DNA [313]. There are two FDA-approved integrase strand transfer 
inhibitors (InSTIs), raltegravir (RAL) and elvitegravir (EVG), Figure 14. Both approved InSTIs 
sequester the IN active site Mg2+ ions through a chelating-triad of hydroxyl- and carboxyl 
functional groups and anchors into a hydrophobic pocket near the active site. The bound InSTI 
sterically blocks the active site from binding to target DNA and inhibits the strand transfer 
reaction [314,315]. 
 
Figure 14: Structures of integrase strand transfer inhibitors 
RAL resistance is clinically associated with three pathways in the IN gene, each defined 
by primary mutations at active-site residues Y143, Q148 or N155, while EVG resistance is only 
associated Q148 or N155 [316,317]. These primary mutations are correlated with secondary 
compensatory mutations; for Y143(C/G/R) these include T97A, L74M and E138A; for 
Q148(H/K/R) these include E138(A/K), G140(A/S) and Y143H; and for N155H these include 
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L74M and E92Q [318]. Significant cross-resistance is observed between the InSTIs irrespective 
of the primary/secondary mutation pathways [316,319].  
1.3.1.13 Fusion inhibitors 
Enfuvirtide (T-20) inhibits HIV-1 gp41 at the final stage of viral fusion with the target cell 
membrane [320]. T-20 is a synthetic peptide with the primary amino acid sequence CH3CO-Tyr-
Thr-Ser-Leu-Ile-His-Ser-Leu-Ile-Glu-Glu-Ser-Gln-Asn-Gln-Gln-Glu-Lys-Asn-Glu-Gln-Glu-
Leu-Leu-Glu-Leu-Asp-Lys-Trp-Ala-Ser-Leu-Trp-Asn-Trp-Phe-NH2. T-20 binds to the heptad-
repeat-1 of the viral Env gp41 and blocks the conformational changes required for the insertion 
of the fusion peptide into the cellular membrane. Resistance to T-20 is mediated by gp41 
mutations G36D, I37T, V38(A/M), N42(D/T) and N43K [321]. 
1.3.1.14 CCR5 antagonists 
Maraviroc (MVC) is the only FDA-approved HIV-1 entry inhibitor, Figure 15 [322]. MVC binds 
to a hydrophobic pocket in the cellular co-receptor CCR5 that alters the conformation of the 
surface protein and prevents interaction with viral Env gp120 [323]. Of note, MVC is the only 
FDA-approved anti-HIV-1 drug that acts on a host target. Viral co-receptor tropism switching is 
a concern in the administration of CCR5 antagonists because infection with CXCR4-tropic virus 
normally leads to faster disease progression [324]. However, tropism switching has only been 
observed in patients with preexisting populations of X4 virus and, therefore, viral tropism must 
be assessed before initializing MVC containing regimens. 
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 Figure 15: Structure of the CCR5 antagonist maraviroc 
1.3.1.15 Recommended Antiretroviral Regimens 
Novel drugs and coformulations are expanding the therapy possibilities for treatment-naïve 
adults infected with drug-susceptible virus. Antiretroviral therapy does not cure HIV-1 infection 
and requires life-long adherence for continuous suppression of viral replication to prevent 
emergence of resistance and viral rebound. NRTIs are largely utilized as the backbone of HIV-1 
therapeutic regimens. The current recommendations of the International Antiviral Society–USA 
Panel for first-line therapy consists of two NRTIs (usually TDF/FTC or ABC/3TC) in 
combination with either 1) a NNRTI (usually EFV or NVP); 2) a ritonavir boosted PI (usually 
darunavir, atazanavir, or lopinavir); 3) an integrase inhibitor (either RAL or EVG) [6]. Fixed 
dose coformulated drugs have been developed to decrease pill burdens for NRTI including: 
3TC/AZT (Combivir), ABC/3TC (Epzicom), TDF/FTC (Truvada), AZT/ABC/3TC (Trizivir) 
and also with multiclass combinations including: EFV/FTC/TDF (Atripla), FTC/RPV/TDF 
(Complera) and EVG/cobicistat/FTC/TDF (Stribald). 
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1.4 RT DRUG RESISTANCE MUTATIONS 
HIV-1 develops resistance to NRTI by the accumulation of mutations within the gene 
encoding RT. The viral genome has a high rate of mutation because RT lacks proofreading 
activity, viral replication is rapid and large quantities of virus are produced [325]. These 
properties manifest in the creation of many quasi-species of HIV-1 within a host. Individual or 
combinations of mutations may be silent or polymorphic, result in replication deficient virus, or 
confer an advantageous phenotype such as drug resistance. Quasi-species that have resistance 
mutations will undergo natural selection during treatment and become the dominant circulating 
population in a patient because non-resistant virus replication will be suppressed.  
The level of resistance to a specific NRTI is determined by the phenotype and number of 
accumulated mutations specific to each drug. This results in distinctive mutational pathways that 
have predictable mechanisms. For example, AZT resistance is mediated by the accumulation of 
TAMs (M41L/L210W/T215Y or D67N/K70R/T215F) in the polymerase domain, A371V in the 
connection domain and Q509L in the RNase H domain that together yield significant (934-fold) 
resistance [286]. The common drug resistance mutations associated with specific FDA-approved 
antiretrovirals are described in Table 1. 
Table 1: NRTI resistance mutations in HIV-1 RT 
NRTI RT residue 
41 65 67 69 70 74 115 184 210 215 219 371 509 
ddI K65R L74V   
TNV K65R K70E   
ABC K65R L74V Y115F M184V   
ddC K65R T69D M184V/I   
3TC/FTC K65R M184V/I   
d4T M41L K65R K67N K70R L210W T215Y/F K219Q/E   
AZT M41L K67N K70R L210W T215Y/F K219Q/E A371V Q509L 
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1.4.1 Multi-NRTI resistance 
The widespread use of HAART has favored the selection of unique patterns of mutations 
conferring multi-drug resistance. The four main patterns observed are K65R, the 69S Insertion 
Complex, the 151M Complex and accumulated TAMs. The mutation K65R confers some 
resistance to all FDA-approved NRTI except AZT. The 69S Insertion Complex consists of a 
dipeptide insertion (Ser-Ser, Ser-Gly or Ser-Ala) between codons 69 and 70 of RT together with 
mutations M41L, A62V, T69S, T215Y and sometimes K70R and is associated with resistance to 
all FDA-approved NRTI [326,327]. The 151M Complex comprises most importantly Q151M 
and also mutations A62V, V75I, F77L and F116Y and is associated with resistance to all FDA-
approved NRTI except TNV [328]. As previously discussed, TAMs (M41L, D67N, K70R, 
L210W, T215Y/F and K219Q/E) are often associated with AZT-resistance, but combinations of 
different TAMs confer cross-resistance to all other FDA-approved NRTI as well [329]. 
1.5 NRTI RESISTANCE MECHANISMS 
The most characterized mechanisms of NRTI resistance are NRTI discrimination that reduces the 
efficiency of NRTI incorporation and NRTI excision that unblocks NRTI-terminated primers 
[330]. These mechanisms are characterized by distinctive biochemical kinetic parameters of RT. 
Cross-resistance between certain NRTIs caused by similar resistance mutation pathways limits 
the options for therapeutic use of the compounds after a patient has previously failed a regimen. 
Therefore, novel NRTIs that do not select for previously described NRTI-associated mutations 
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are desired. However, current paradigms cannot predict the influence of NRTI structure on 
resistance mutations or mechanisms.  
1.5.1 Discrimination 
This mechanism allows mutant RT to selectively incorporate natural dNTP molecules over the 
NRTI-triphosphate. The catalytic efficiency is determined by two kinetic factors: the maximum 
rate of nucleotide incorporation (kpol) and the rate of the nucleotide dissociation from the RT 
polymerase active site (Kd), however the effects of most selected mutations only affect one 
value, Table 2. These parameters are experimentally determined by pre-steady-state kinetic 
analysis through the use of stopped-flow rapid quench technology [165]. 
 
Table 2: Mechanisms and Resistance of Discrimination 
Mutation Mechanism NRTI Resistance 
K65R ? kpol ddI, TNV, ABC, ddC, 3TC, FTC, d4T 
K70E ? kpol TNV, ABC, 3TC 
L74V ? kpol ddI, ABC, ddC 
aQ151M ? kpol ddI, ABC, ddC, 3TC, FTC, d4T, AZT 
M184I/V ? Kd ddI, ABC, 3TC, FTC 
a Q151M Complex contains Q151M and also mutations A62V, V75I, F77L and F116Y. 
1.5.2 Excision 
This mechanism allows mutant RT to catalyze ATP- or pyrophosphate-mediated removal of an 
incorporated NRTI-MP from a chain-terminated primer. Primer unblocking restores the 3’-
hydroxyl group of the -1 nucleotide of the primer strand and allows RT to resume polymerization 
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until another NRTI-MP is added. Only TAMs and the 69S Insertion Complex have been 
associated with excision activity. 
The terminating NRTI-MP must be located in the N-site of the RT polymerase active site 
for the excision reaction to occur. Binding of the next correct nucleotide can prevent excision by 
translocating the primer-NRTI-MP into the P-site. This is forms a dead-end complex because RT 
is unable to polymerase as a result of the incorporated NRTI-MP and is unable to excise the 
compound due to its position in the P-site [331]. Biochemical analyses provide evidence for 
several mechanisms for increased excision in RT with TAMs, including binding ATP in an 
orientation that positions the γ-phosphate for nucleophilic attack, faster rate of excision of the 
terminator and a shift in the equilibrium favoring the terminating NRTI-MP in the N-site over 
the P-site [332-335]. 
Although AZT-MP is the most efficient FDA-approved substrate for excision, other 
terminating NRTI-MP can be removed as well. Different factors impact the ability of a the 
NRTI-MP to be excised, such as the base and sugar structures of the active nucleotide analog 
[336]. The 3’-azido group of AZT-MP is not the primary determining factor for excision because 
3’-azido-2’,3’-ddC, and 3’-azido-2’,3’-ddU are also efficiently removed from the end of a 
terminated primer by TAM containing RT, while the excision rates for 3’-azido-2’-3’-ddA and 
3’-azido-2’,3’-ddG are significantly reduced [337]. Current evidence suggests that the 
pyrimidine-based inhibitors are better substrates than their purine-based analogs. The sequence 
and type of template (RNA or DNA) can also influence the rates of excision. Rescue of DNA 
synthesis happens at similar rates on primers annealed to either DNA or RNA templates, 
however the amount of terminator removed from a RNA-bound primer is less than a DNA-bound 
primer of identical sequence. This suggests that the rate of excision is faster in the context of a 
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DNA primer. Additionally, excision by TAM containing RT is not efficient during the initiation 
of minus-strand DNA synthesis, providing evidence that NRTI-mediated inhibition varies during 
different stages of the reverse transcription [338,339].  
The RNase H activity of RT has also been implicated to influence excision rates of a 
terminated primer bound to an RNA template. Two mechanisms are possible for the enhanced 
excision by decreased RNase H activity, including decreased template switching during reverse 
transcription and template preservation to provide an increased amount of time available for 
excision. This is supported by the observations that mutations in the RNase H primer-grip region 
or connection subdomain increase AZT-resistance and accelerated excision by bound EFV 
decrease AZT-resistance in TAM containing RT [340-343]. 
1.6 IMPORTANCE OF NRTI DISCOVERY 
NRTI drug resistance can severely limit the therapeutic options for an HIV-1 infected individual, 
so new analog with favorable cross-resistance profiles are constantly desired. NRTI have been 
historically discovered by the initial synthesis of novel compounds, followed by the empirical 
testing for in vitro cytotoxicity and antiretroviral activity against wild-type or drug-resistant 
virus. This is a cumbersome process and has the potential to miss highly active compounds 
because the structural determinants of activity may not be known. Our group has previously 
conducted numerous studies to systematically determine various contributions of both the sugar 
structure and base towards an individual NRTI’s anti-HIV-1 activity. This knowledge has 
contributed to the rational design of novel analogs with activity against virus with TAM 
containing RT. 
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1.6.1 Structurally diverse analogs 
Our group has previously completed a systematic evaluation of a series of related, but 
structurally diverse, NRTI to identify the structural components of analogs that confer anti-HIV-
1 activity in vitro [336].  It was found that both the sugar and base moieties influenced the 
antiviral activities in a predicable manner in respect to RT with the multi-NRTI resistance 
mutation K65R. The most potent sugar structure for the inhibition of this resistant virus was 3’-
azido-2’,3’-dideoxyribose that showed little to no resistance over wild-type virus. All other 
analogs tested (2’,3’-dideoxy-, 2’,3’-didehydro-, 2’-fluoro-2’,3’-didehydro-, 3’-thia-2’,3’-
dideoxy-, L-3’-thia-2’,3’-dideoxy-, D- or L-dioxolane- ribose) showed levels of resistance 
ranging from 2.3- to 77-fold over wild-type virus. Additionally, the base structure was identified 
to be an important factor for activity. For the 3’-azido-2’,3’-dideoxy series of analogs , the order 
of activity by EC50 values was T > A > G > C (ranging from 0.20 to 15.0 μM), and the order of 
resistance by K65R virus was C > G > T > A (ranging from 2.5- to 0.9-fold resistance over wild-
type). However, it was not known if these analogs would retain activity against a virus 
containing the AZT-resistant TAMs. 
1.6.2 Importance of 3’-azido-2’,3’-dideoxypurine analogs 
Our group has previously performed in depth biochemical analysis of the 3’-azido-2’,3’-dideoxy 
series of analogs to determine the kinetics of incorporation and excision, as well as to determine 
the in vitro inhibition of virus with AZT-resistance mutations. Purified wild-type or TAM 
containing RT (D67N/K70R/T215F/K219Q) was used to determine the ability to incorporate and 
then excise each analog, Figure 16. It was confirmed that TAM containing RT is more efficient 
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than the wild-type RT in this regard for AZT, as expected, as well as 3′-azido-2′,3′-
dideoxycytidine (3′-azido-ddC), but not either 3′-azido-2′,3′-dideoxyguanosine (3′-azido-ddG), 
or 3′-azido-2′,3′-dideoxyadenosine (3′-azido-ddA) [337]. 
 
 
Figure 16: Relative efficiency of excision to incorporation of 3'-azido-ddNucleotides 
Each 3’-azido-ddNucleotide (T,Thymidine; C, Cytidine; A, Adenosine; G, Guanosine) was 
evaluated in vitro for excision and incorporation activity by wild-type (grey bars) or TAM 
containing (black bars) purified recombinant RT. The individual values for the catalytic 
efficiency of excision and incorporation were previously determined [337]. 
 
 The HIV-1 susceptibility of each analog was tested in vitro with virus containing wild-
type or TAM containing RT. The results correlated well with the biochemical data in that the 
TAMs conferred resistance to both AZT (11.7-fold over wild-type) and 3′-azido-ddC (10.7-fold 
over wild-type), but not either 3′-azido-ddG (1.3-fold over wild-type) or 3′-azido-ddA (1.2-fold 
over wild-type), Table 3 [337]. 
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Table 3: Antiviral activity of 3’-azido-ddN analogs 
  aEC50, μM 
Base HIVWT bHIVTAMs cFold Resistance 
T 0.031 ± 0.02 0.36 ± 0.2 11.7 
C 15.6 ± 10.7 160.8 ± 24.1 10.7 
G 7.09 ± 4.63 10.3 ± 8.3 1.3 
A 7.9 ± 3.4 8.6 ± 5.4 1.1 
a data are the mean ± standard deviation of three independent experiments determined in 
P4/R5 cells [337].  
b HIVTAMS is HIV-1 with RT mutations at D67N/K70R/T215F/K219Q.  
c Fold resistance is determined as EC50 HIVTAMS/ EC50 HIVWT. 
 
Further studies show that 3′-azido-ddG and 3′-azido-ddA have anti-HIV-1 activity in a 
variety of cell types including P4/R5 (HeLa-based reporter cell line), MT-2 (HTLV-1 infected 
human T cell line) and primary human peripheral blood mononuclear cells (PBMC) with EC50 
values ranging from approximately 0.2 to 10 μM [344]. The activities of these compounds were 
also evaluated against a panel of viruses harboring a variety of common NRTI-resistance 
mutations, Table 4 [344]. It was observed that the 3’-azido-2’,3’-dideoxypurine analogs are 
potent inhibitors of these viruses, though there was some resistance associated with the  69S 
Insertion and Q151M Complexes. Although 3’-azido-ddA appears to retain slightly more 
resistance against known drug resistance mutations, 3’-azido-ddG has additional favorable 
properties that make it desirable. There was low cytotoxicity of 3’-azido-2’,3’-ddG (CC50 range 
of >100 to >270 μM) across five different types of cells including PBMC, MT-2, P4/R5, Vero 
(C. sabaeus epithelial kidney cell line), CEM (Human T cell lymphoblast-like cell line) and 
HepG2 (human hepatocellular carcinoma cell line). Additionally, there was a linear dose-
response for the cellular uptake of 3’-azido-2’,3’-ddG and metabolism to the active triphosphate 
compound with a intracellular half-life of  approximately 9 hours. The cytotoxicity of 3’-azido-
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ddA was more substantial with CC50 values of 74.3 μM (PBMC) and 50.6 μM (both Vero and 
CEM cell lines). Additionally, 3’-azido-ddG did not show signs of mitochondrial toxicity, while 
3’-azido-ddA decreased the physical amount of mtDNA and increased lactic acid production 
[344]. 
Table 4: Antiviral activity of 3'-azido-2',3'-dideoxypurine analogs 
aEC50, μM (fold-resistance) 
Virus AZT 3'-Azido-ddG 3'-Azido-ddA
WT 0.19 ± 0.11 2.1 ± 0.9 10.7 ± 4.9
K65R 0.21 ± 0.15 (1.1) 5.0 ± 1.3 (2.3) 9.8 ± 8.4 (0.9)
L74V 0.21 ± 0.08 (1.1) 2.9 ± 0.9 (1.4) 13.7 ± 5.7 (1.2)
M184V 0.18 ± 0.16 (1.0) 1.7 ± 0.1 (0.8) 8.9 ± 2.3 (0.8)
bQ151M 213.7 ± 12.3 (1,124) 72.9 ± 29.5 (34.7) 70.1 ± 10.8 (6.5)
cTAM1 10.4 ± 8.9 (54) 5.2 ± 2.3 (2.5) 24.2 ± 3.7 (2.2)
dTAM2 11.9 ± 11.6 (62) 3.7 ± 1.4 (1.8) 19.4 ± 8.1 (1.8)
eTAM3 96.7 ± 29.3 (507) 7.6 ± 2.2 (3.5) 31.6 ± 3.7 (2.9)
fTAM4 58.6 ± 9.2 (307) 7.9 ± 4.9 (3.7) 37.5 ± 6.2 (3.5)
g69SS 204.6 ± 18.6 (1,076) 26.4 ± 8.8 (12.5) 29.9 ± 5.9 (2.8)
a data are the mean ± standard deviation of three independent experiments determined 
in P4/R5 cells [337].  
b Q151M Complex contains Q151M and also mutations A62V, V75I, F77L and 
F116Y.  
c M41L/L210W/T215Y.  
d D67N/K70R/T215F/K219Q.  
e M41L/D67N/K70R/T215F/K219Q.  
f M41L/D67N/K70R/L210W/T215Y/K219Q.  
g 69SS Insertion Complex consists of a dipeptide insertion (Ser-Ser) between codons 
69 and 70 of RT together with mutations M41L/A62V/T69S/T215Y. 
 
The 3’-azido-2’,3’-dideoxypurine sub-class of NRTI are potent inhibitors of HIV-1 even 
in the presence of most RT-resistance mutations. Importantly, it should be noted that these 
compounds were previously identified, but overshadowed by the contemporary development of 
other compounds due initial toxicity studies [345-347]. The selected mutations and associated 
mechanisms resistance are not known for these compounds. We aim to delineate these properties 
in vitro to provide further evidence for the usefulness of this sub-class of NRTI.  
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2.0  HYPOTHESIS AND SPECIFIC AIMS 
Drug resistance limits the usefulness of current NRTIs [348]. Resistance barriers and the degree 
of cross-resistance within the class of NRTI are variable. There is a clinical need to expand the 
repertoire of potent antiretroviral compounds that are active against drug-resistant HIV-1 RT. It 
has been shown that the base structure of a 3’-azido-2’,3’-dideoxynucleoside influences its 
antiretroviral activity [337]. Of particular interest, AZT-resistant HIV-1 remains susceptible to 
3’-azido-2’,3’-dideoxypurine analogs (ADP). This finding may be exploited for rational drug 
design of novel NRTI with similar activities. The goals of this study are to characterize base-
modified ADPs that are active against drug-resistant virus and to define the structural 
components of ADPs that are important for antiviral activity and resistance. 
Cell-based and biochemical methods will be used to investigate a panel of 3’-azido-2’,3’-
dideoxynucleoside compounds with different base structures to determine the relationship 
between structure, activity and resistance. This will define chemical moieties that will aid in 
rationale drug design and development. 
2.1 HYPOTHESES 
Nucleoside analogs consisting of different base structures and identical 3’-azido-2’,3’-
dideoxyribose sugar structures will have different antiretroviral activities and will select for 
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different resistance mutations in vitro. The biochemical mechanisms of resistance by different 
mutations will differ based upon which mutations are selected. The cytidine and thymidine 
analogs, including the well-studied AZT, will have similar profiles and the guanosine and 
adenosine analogs will have similar profiles, but the profiles of the pyrimidine-based analogs 
will be markedly different than the purine-based analogs in respect to antiretroviral activities, 
selected resistance mutations and biochemical mechanisms of resistance. 
2.2 SPECIFIC AIMS 
2.2.1 Aim 1 
To determine the antiretroviral activity and selected resistance 3′-azido-ddG, 3′-azido-ddC, or 3′-
azido-ddA, Figure 17, will be tested in cell culture by single-cycle or multiple-cycle viral assays 
to determine median 50% inhibitory concentrations (EC50), resistant virus will be produced by 
passaging virions through increasing concentrations of each individual nucleoside analog and the 
mutation profiles of the selected viruses will be examined. Population and single genome DNA 
sequencing will be used to identify mutations and the influence of each mutation on drug 
susceptibility and cross-resistance will be resolved using recombinant viruses generated by site-
directed mutagenesis or cloning entire RT sequenced isolated from individual genomes. 
Structure-resistance relationships of base-modified ADP compounds will be defined with respect 
to their influence on both antiretroviral activity and selected resistance. 
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 Figure 17: Structures of 3'-azido-2',3'-dideoxynucleoside analogs 
A. 3′-azido-ddT (AZT), B. 3′-azido-ddC, C. 3′-azido-ddG, D. 3′-azido-ddA 
2.2.2 Aim 2 
Purified recombinant RT from site-directed mutagenesis and isolated RT sequence clones will be 
used to investigate the biochemical mechanisms of resistance. The purified enzymes will be 
assayed for steady-state polymerase activities, steady-state ATP-mediated excision, steady-state 
RNase H cleavage, pre-steady-state single-nucleotide incorporation and RT-Template/Primer 
binding affinity.  
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3.1 PREFACE 
This chapter is adapted with permission from a published study (Meteer, J.D., Koontz, D., Asif, 
G. Zhang, H., Detorio, M., Solomon, S., Coats, S.J., Sluis-Cremer, N., Schinazi, R.F. and 
Mellors, J.W. 2011. The Base Component of 3′-Azido-2′,3′-Dideoxynucleosides Influences 
Resistance Mutations Selected in HIV-1 Reverse Transcriptase. Antimicrob Agents Chemother, 
55(8): p. 3758–3764). Copyright © 2011, American Society for Microbiology. 
Additionally, this study was presented in part as an oral presentation and poster at the 17th 
International HIV Drug Resistance Workshop, Sitges, Spain, 2008 (Abstract 3, published in 
Meteer, J., Koontz, D., Rapp, K.L., Detorio, M., Ruckstuhl, M., Schinazi, R.F., Mellors, J.W. 
Novel resistance profile of the potent nucleoside analogue reverse trascriptase inhibitor 3’-azido-
2’,3’-dideoxyguanosine. Antiviral Therapy, 2008, 13 Suppl 3:A5); in part as a poster at the 
International HIV & Hepatitis Virus Drug Resistance Workshop & Curative Strategies, 
Dubrovnik, Croatia, June 2010 (Abstract 67 published in Meteer, J., Koontz, D., Schinazi, R.F., 
Sluis-Cremer, N., Mellors, J.W. 2010. The base component of 3’-azido-2’,3’-dideoxynucleosides 
determines the mutation patterns selected in HIV-1 reverse transcriptase. Antiviral Therapy, 
2010, 15 Suppl 2:A81). 
The work presented in this chapter is in partial fulfillment of dissertation Aim 1. Jeffrey 
Meteer performed all experimental work with the exception of AZT selection experiments 
completed by Dianna Koontz and the quantitation of metabolism of 3’-azido-2’,3’-ddA by 
Ghazia Asif, Hong-wang Zhang, Mervi Detorio and Sarah Solomon. 
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3.2 ABSTRACT 
We recently reported that HIV-1 resistant to 3′-azido-3′-deoxythymidine (AZT) is not cross-
resistant to 3′-azido-2′,3′-dideoxypurines. This finding suggested that the nucleoside base is a 
major determinant of HIV-1 resistance to nucleoside analogs. To further explore this hypothesis, 
we conducted in vitro selection experiments by serial passage of HIV-1LAI in MT-2 cells in 
increasing concentrations of 3′-azido-2′,3′-dideoxyguanosine (3′-azido-ddG), 3′-azido-2′,3′-
dideoxycytidine (3′-azido-ddC), or 3′-azido-2′,3′-dideoxyadenosine (3′-azido-ddA). 3′-Azido-
ddG selected for virus that was 5.3-fold resistant to 3′-azido-ddG compared to wild-type HIV-
1LAI passaged in the absence of drug. Population sequencing of the entire reverse transcriptase 
(RT) gene identified L74V, F77L, and L214F mutations in the polymerase domain and K476N 
and V518I mutations in the RNase H domain. However, when introduced into HIV-1 by site-
directed mutagenesis, these 5 mutations only conferred ~2.0-fold resistance. Single-genome 
sequencing analyses of the selected virus revealed a complex population of mutants that all 
contained L74V and L214F linked to other mutations, including ones not identified during 
population sequencing. Recombinant HIV-1 clones containing RT derived from single sequences 
exhibited 3.2- to 4.0-fold 3′-azido-ddG resistance. In contrast to 3′-azido-ddG, 3′-azido-ddC 
selected for the V75I mutation in HIV-1 RT that conferred 5.9-fold resistance, compared to the 
wild-type virus. Interestingly, we were unable to select HIV-1 that was resistant to 3′-azido-ddA, 
even at concentrations of 3′-azido-ddA that yielded high intracellular levels of 3′-azido-ddA-5′-
triphosphate. Taken together, these findings show that the nucleoside base is a major determinant 
of HIV-1 resistance mechanisms that can be exploited in the design of novel nucleoside RT 
inhibitors. 
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3.3 GOAL OF STUDY 
Drug resistance limits the usefulness of current approved NRTI. Resistance barriers and the 
degree of cross-resistance within the class of NRTI are variable. There is a clinical need to 
expand the repertoire of potent antiretroviral compounds that are active against drug resistant 
HIV-1 RT. It was recently shown that the base structure of the 3’-azido-2’,3’-dideoxynucleoside 
influenced its activity [337]. Of particular interest, AZT-resistant HIV-1 remains susceptible to 
purine analogs, 3’-azido-2’,3’-ddG and 3’-azido-2’,3’-ddA. This finding may be exploited for 
rational drug design of novel NRTI with similar activities. The goal of this study was to 
characterize the RT mutations selected by in vitro passage of virus in the presence of 3’-azido-
nucleoside analogs and to define the importance of the mutations by site-directed mutagenesis. 
3.4 MATERIALS AND METHODS 
3.4.1 Nucleosides 
3′-azido-ddA and 3′-azido-ddG were obtained from Berry Associates, Inc. (Ann Arbor, MI). 
AZT and ddI were obtained from Sigma Chemical Corporation (St. Louis, MO). ABC was 
obtained from GlaxoSmithKline (Research Triangle Park, NC). TFV was obtained from the 
AIDS Research and Reference Reagent Program (Division of AIDS, NIAID, NIH). 3′-azido-
ddC, 3TC, and d4T were kindly provided by Raymond Schinazi (Emory University). 3′-azido-
ddA-5′-triphosphate was synthesized as previously described [349]. All NRTIs were prepared as 
40 mM stock solutions in dimethyl sulfoxide or sterile water and stored at −20°C. 
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3.4.2 Cells and viruses 
MT-2 cells (AIDS Research and Reference Reagent Program) were cultured in RPMI 1640 with 
2 mM l-glutamine (Lonza, Walkersville, MD) supplemented with 10% fetal bovine serum 
(HyClone Laboratories, Inc., Logan, UT), 10 mM HEPES buffer (Gibco, Grand Island, NY), and 
50 IU/ml of penicillin and 50 μg/ml of streptomycin (Gibco). The P4/R5 reporter cell line 
(provided by Nathaniel Landau, Salk Institute, La Jolla, CA), which expresses the β-
galactosidase gene under the control of the HIV-1 long terminal repeat promoter that is 
transactivated by HIV-1 tat, was maintained in phenol red-free Dulbecco's modified Eagle 
medium (Gibco) supplemented with 10% fetal bovine serum, 50 IU/ml of penicillin, 50 μg/ml of 
streptomycin, and 0.5 μg/ml of puromycin (Clontech, Palo Alto, CA). Stock viruses were 
prepared in MT-2 cells as described previously [336]. Briefly, 5 μg of plasmid DNA was 
electroporated into 1.3 × 107 MT-2 cells. Cell-free supernatants were collected 5 to 7 days 
posttransfection at peak cytopathic effect (CPE) and stored at −80°C. The infectivities of the 
virus stocks were determined by 3-fold end point dilution in P4/R5 cells, and the 50% tissue 
culture infectivity dose was calculated using the Reed and Muench equation [350]. 
3.4.3 Selection of drug-resistant HIV-1 
Resistant virus was selected by serial passage of wild-type (WT) xxHIVLAI in MT-2 cells in 
increasing concentrations of 3′-azido-ddG, 3′-azido-ddC, or 3′-azido-ddA. To initiate each 
selection experiment, MT-2 cells (1 × 106) were pretreated for 2 h with twice the concentration 
of drug required to inhibit viral replication by 50% (EC50) of the nucleoside analog before 
inoculation with virus. Viral replication was monitored by CPE. At three or four syncytia per 
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field at 100× magnification, the cell-free supernatant was harvested and 0.1 ml of supernatant 
was added to fresh MT-2 cells to initiate a new passage. Remaining supernatant was stored 
frozen at −80°C. The concentration of drug was doubled every 5 to 15 passages, as viral growth 
permitted. Mean EC50 values (n = 3) were determined at every five passages to identify changes 
in drug susceptibility. Fold resistance was calculated by dividing the mean EC50 of the passaged 
virus by the mean EC50 of wild-type HIV-1LAI. The population genotype of the virus was 
determined every 10 passages by standard automated sequencing. 
3.4.4 Drug susceptibility assays 
NRTI susceptibility was determined in P4/R5 cells as described previously [336]. Briefly, 3-fold 
dilutions of inhibitor were added to P4/R5 cells in triplicate, and the cells were infected with an 
amount of virus that produced 100 relative light units (RLU) in no-drug virus control wells. After 
48 h, the cells were lysed (Gal-Screen; Tropix/Applied Biosystems, Foster City, CA) and the 
RLU were measured using a ThermoLab Systems luminometer (Waltham, MA). The EC50 and 
fold resistance were calculated as described above. 3′-azido-ddC is not well phosphorylated in 
P4/R5 cells, and the 3′-azido-ddC-selected virus did not grow well in P4/R5 cells. Susceptibility 
to 3′-azido-ddC was therefore determined in MT-2 cells, and viral replication was quantified by 
measuring p24 antigen production (Perkin-Elmer, Inc., Waltham, MA). 
3.4.5 HIV-1 population sequencing 
To confirm the genotypes of virus populations, viral RNA was extracted from culture 
supernatants by using oligo(dT)25 Dynabeads (Invitrogen, Carlsbad, CA) according to the 
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manufacturer's instructions and treated with 1 IU/μl of DNase I for 2 h. The RNA was converted 
into cDNA and amplified using the SuperScript III one-step RT-PCR system with Platinum Taq 
DNA polymerase (Invitrogen). The entire coding region of RT was amplified using the forward 
primer 5′-GCTCTATTAGATACAGGAGCAGATGAT-3′ and the reverse primer  
5′-CCTTCTAAATGTGTACAATCTAGTTGCCAT-3′. PCR products were purified (Wizard SV 
Gel and PCR Clean-Up system; Promega, Madison, WI) and sequenced using a Big Dye 
terminator kit (v.3.1) on an ABI 3130 automated DNA sequencer (Applied Biosystems, Foster 
City, CA). The following forward primers were used for sequencing RT:  
 1. 5′-GGACCTACACCTGTCAAC-3′ 
2. 5′-GTTCCCTTAGATGAAGAC-3′ 
 3. 5′-GAGGAACCAAAGCACTAA-3′ 
 4. 5′-CACCCTAACTGACACACC-3′ 
3.4.6 Construction of mutant recombinant HIV-1 
Mutant RT clones were generated by site-directed mutagenesis (QuikChange Lightning site-
directed mutagenesis kit; Stratagene, La Jolla, CA) using the p6HRT-MO plasmid. This plasmid 
contains the entire RT and protease coding sequence and four silent restriction sites (XmaI, MluI, 
XbaI, and NgoMIV from the 5′ to 3′ end of RT at codons 14, 358, 490, and 554, respectively) 
[286]. After site-directed mutagenesis, the mutated RT was ligated into pxxHIV-1LAI-MO, which 
contains the entire genome of HIV-1LAI and the same silent restriction sites in RT as p6HRT-
MO. Infectious virus was generated by electroporation of the mutated xxHIV-1LAI-MO plasmid 
into MT-2 cells as described above. All mutations in recombinant viruses were confirmed by 
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full-length sequencing of the entire RT coding region. Plasmids were kindly provided by Jessica 
Brehm (University of Pittsburgh). 
3.4.7 SGS and generation of recombinant infectious viruses 
Full-length RT sequences from single viral genomes in passaged virus were obtained by isolating 
viral RNA (as described above) and synthesizing cDNA with SuperScript III reverse 
transcriptase (Invitrogen) and primer 4232 (5′-TTCCCTACAATCCCCAAAGTCAAGG-3′). 
The cDNA was then serially diluted to yield 30% positive PCRs as described elsewhere for 
single-genome sequencing (SGS) [351]. First-round PCR was performed using AmpliTaq Gold 
(Applied Biosystems), primer 4232, and primer Bcl (5′-
AGGAAGAATGGAAACCAAAAATGATAG-3′). Second-round PCR was performed using 
primers Bcl and 3908 (5′-CAAAAGAAATAGTAGCCAGCTGTG-3′). Positive reactions were 
determined by gel electrophoresis, purified by treatment with ExoSAP-IT (USB, Cleveland, 
OH), and sequenced as described above [351]. To generate infectious recombinant clones 
derived from single viral genomes, full-length RT was amplified from purified first-round PCR 
product using the following primers containing restriction sites:  
1989Bcl, 5′-GTTTTATCAAAGTAAGACAGTATGATCAGATAC-3′;  
Sgr, 5′-TAACCTGCCACCGGTGGTAG-3′.  
The purified products were concatemerized, digested with BclI and SgrAI, and cloned into 
pxxLAI-3D [pxxLAI-MO with 4 additional silent restriction sites: BclI (nucleotide [nt] 2011), 
BstBI (nt 3096), HpaI (nt 3383), and SgrAI (nt 3897)]. The recombinant plasmid was used to 
produce infectious virus as described above. Primers and plasmid were kindly provided by 
Jessica Brehm (University of Pittsburgh). 
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3.4.8 Cellular metabolism of 3′-azido-ddA 
MT-2 cells (5 × 106) were incubated for 4 h with 3′-azido-ddA at 5, 12.5, 25, and 50 μM 3′-
azido-ddA. The cells were then centrifuged for 10 min at 350 × g at 4°C, and the pellet was 
resuspended and washed three times with cold phosphate-buffered saline. Nucleoside 
triphosphates were extracted by incubation overnight at −20°C with 1 ml 60% methanol–water. 
The supernatants were then collected and centrifuged at 16,000 × g for 5 min. The pellets were 
then reextracted for 1 h on ice by using an additional 200 μl of 60% methanol in water, followed 
by centrifugation at 16,000 × g for 5 min. The extracts were combined, dried under a gentle 
filtered airflow, and stored at −20°C. The residues were resuspended in 100 μl of water prior to 
liquid chromatography (LC)-tandem mass spectrometry analysis. 
The LC system was an UltiMate 3000 modular system (Dionex, Sunnyvale, CA) 
consisting of a quaternary pump, vacuum degasser, thermostated autosampler (4°C), and 
thermostated column compartment (28°C). An API5000 mass spectrometer (AB/SCIEX, Foster 
City, CA) was used as a detector. LC Analyst software version 1.4.2 was used to control both the 
LC and the mass spectrometer and for the data analysis and quantification. Phosphorylated 3′-
azido-ddA was quantified by ion exchange, with the separation performed on a 5-μm-particle-
size Biobasic C18 (50- by 1.0-mm) column (Thermo Electron, Bellefonte, PA) using a gradient. 
The mobile phase consisted of A (10 mM ammonium acetate), B (ammonia buffer [pH 9.6]), and 
C, acetonitrile. Sample volumes of 5 μl were injected onto the column. 
The flow was diverted to waste for the initial 1 min of the analysis. Initial composition of 
the mobile phase was 70% A and 30% C with a gradient at 3.5 min to 70% B and 30% C for 5 
min. The mass spectrometer was operated in positive ionization mode with a spray voltage of 5 
kV, gas 1 at 15 (arbitrary units), gas 2 at 20 (arbitrary units), and source temperature of 230°C. A 
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standard curve was prepared by spiking 8 standards of synthesized 3′-azido-ddA-5′-TP in the 
range of 1 nM to 500 nM in cell lysate. The precursor-product ion transitions, declustering 
potential (DP, in V), collision energies (CE, in V), and exit potential (CXP, in V) for 3′-azido-
ddA-DP and -TP were m/z 437.2 → m/z 136; DP 121, CE 29, CXP 14; m/z 517.2 → m/z 136; 
DP 121, CE 31, CXP 14, respectively. 
3.5 RESULTS 
3.5.1 Selection of HIV-1 resistance to 3′-azido-ddG 
Wild-type HIV-1LAI was serially passaged in MT-2 cells in increasing concentrations of 3′-azido-
ddG. After every fifth passage, 3′-azido-ddG susceptibility of the passaged virus was determined 
in a single-cycle replication inhibition assay in P4/R5 cells, Figure 18. Full-length RT genotype 
analysis of the virus population (i.e., population genotype) was determined every 10th passage, 
Figure 18. L74V was the first mutation to emerge at passage 10, followed by L214F at passage 
30, V518I at passage 60, and K476N and F77L at passage 90, Figure 18. The final virus 
population contained all 5 mutations and was 5.3-fold more resistant than a control xxHIV-1LAI 
that was passaged in parallel in the absence of drug. No RT mutations were detected in the 
control virus.  
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 Figure 18: In vitro selection of 3'-azido-ddG resistant HIV-1 
3′-azido-ddG-resistant xxHIV-1LAI was selected by serial passage of virus in increasing 
concentrations of 3′-azido-ddG. Passaged virus was phenotyped for 3′-azido-ddG susceptibility 
(EC50, 10.1 ± 2.5 μM at passage 88) and compared to the control wild-type xxHIV-1LAI passaged 
in parallel without 3′-azido-ddG (EC50, 1.91 ± 1.16 μM at passage 88) to determine resistance at 
every fifth passage. Standard population sequencing was performed at every 10th passage and 
identified the indicated RT mutations that differed from the starting virus population. 
 
Next, we tested the susceptibility of 3′-azido-ddG-resistant virus from passage 88 to a 
panel of NRTIs in P4/R5 cells, Table 5. The 3′-azido-ddG-resistant HIV-1 showed cross-
resistance to ddI (6.2-fold), 3TC (4.8-fold), and ABC (4.2-fold). Low-level cross-resistance was 
also noted for TFV (2.5-fold), D4T (1.5-fold), and 3′-azido-ddA (1.5-fold). 3′-azido-ddG-
resistant HIV-1 remained sensitive to AZT. 
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Table 5: Resistance and cross-resistance of wild-type (WT) and 3'-azido-ddG-selected virus 
 aEC50, μM  
Drug bWT 
cSelected 
Virus 
dFold 
Resistance 
eP value 
ddI 4.3 ± 0.2 26.6 ± 1.2 6.2 <0.0001 
3’-azido-ddG 1.9 ± 1.2 10.1 ± 2.5 5.3 <0.001 
3TC 2.2 ± 1.8 10.5 ± 4.1 4.8 <0.05 
ABC 8.9 ± 0.5 37.2 ± 6.3 4.2 <0.05 
TFV 2.1 ± 0.7 5.4 ± 0.7 2.5 <0.05 
d4T 14.1 ± 3.0 23.2 ± 1.1 1.5 <0.01 
3’-azido-ddA 3.7 ± 0.6 5.6 ± 0.2 1.5 <0.05 
AZT 0.3 ± 0.2 0.4 ± 0.3 1.3 NS 
a Mean ± standard deviation of three experiments. 
b WT virus passaged in parallel with the 3’-azido-ddG selection virus in the absence of drug; 
genotype confirmed by sequencing. 
c Virus isolated from passage 88 of the 3’-azido-ddG selection that contained L74V, F77L, 
L214F, K476N, and V518I by standard population sequencing. 
d Fold resistance determined compared with wild-type xxHIV-1LAI. 
e Statistical significance compared to wild-type xxHIV-1LAI determined by two-sample 
Student’s t test. NS, not significant. 
3.5.2 3′-azido-ddG susceptibilities of viruses containing different combinations of L74V, 
F77L, L214F, K476N, and V518I 
Recombinant viruses were generated by site-directed mutagenesis to contain different 
combinations of the L74V, F77L, L214F, K476N, and V518I mutations. Surprisingly, many of 
the recombinant viruses (e.g., K476N, L74V/L214F/K476N/V518I, and 
L74V/F77L/L214F/K476N/V518I) were growth defective, precluding further assessments of 
NRTI susceptibility, Table 6. Drug susceptibility assays in P4/R5 cells revealed that the F77L, 
L214F, and V518I mutations alone did not confer 3′-azido-ddG resistance, Table 6. Interestingly, 
the remaining recombinant viruses only displayed low levels (1.5- to 2.1-fold over WT) of 3′-
azido-ddG resistance. This finding suggested that population sequencing did not provide an 
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adequate representation of the mutant variants within the selected virus population. Specifically, 
the results suggested that mutations identified by population sequencing showed variable linkage 
on viral genomes and that other important mutations may not have been detected. 
Table 6: 3'-Azido-ddG and 3'-azido-ddC susceptibilities of HIV-1LAI mutants 
aVirus bEC50, µM cFold-Resistance dP value 
3’-Azido-ddG susceptibility    
Wild-type 1.5 ± 0.4 - - 
L74V 2.2 ± 0.5 1.5 NS 
L74V/L214F 2.8 ± 0.4 1.9 <0.05 
L74V/L214F/K476N 3.1 ± 0.3 2.1 <0.005 
L74V/L214F/V518I 2.2 ± 0.9 1.5 NS 
L74V/F77L/L214F/K476N 2.8 ± 0.2 1.9 <0.05 
eK476N - - - 
eL74V/L214F/K476N/V518I - - - 
eL74V/F77L/L214F/K476N/V518I - - - 
    
3’-Azido-ddC susceptibility    
Wild-type 0.6 ± 0.2 - - 
V75I 1.6 ± 0.8 2.6 <0.05 
a Mutants were created in pxxLAI-MO by site-specific mutagenesis and infectious virus was 
produced by transfection of MT-2. 
b Mean ± standard deviation of three experiments. 
c Fold resistance determined against wild-type xxHIV-1LAI-MO clone. 
d Statistical significance compared to wild-type xxHIV-1LAI-MO determined by two-sample 
Student’s t test. NS, not significant. 
e
 The mutant virus was growth defective. 
 
3.5.3 Single-genome sequencing and cloning of RT from the 3′-azido-ddG-resistant HIV-1 
We performed single-genome sequencing analyses of full-length RT from virus at passage 90 to 
genetically characterize individual mutant variants within the selected virus population. This 
approach permitted more detailed analysis of selected viruses, including mutation linkage. Table 
7 shows the mutational patterns observed in 22 single genome sequences. Interestingly, all of the 
sequences contained the L74V and L214F mutations. The F77L (91% of sequences), K476N 
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(68%), and V106I (50%) mutations were also frequently observed in the single genome 
sequences. By contrast, the frequencies of other mutations varied considerably (Table 7), and no 
obvious pattern of linkage emerged from this study. 
 
Table 7: Predicted amino acid changes from wild-type RT in single genome sequences derived from 3'-azido-
ddG-selected virus (passage 90) 
RT 
residue 
Sequence no. % of 
clones 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 
L74 V V V V V V V V V V V V V V V V V V V V V V 100 
F77 L L L L  L L L L L L L L L L L L L L L L  91 
V106 I I I I  I   I  I I    I  I   I  50 
E122 K K    K K    K     K  K   K  36 
E169         K              5 
L214 F F F F F F F F F F F F F F F F F F F F F F 100 
R277 K  K          K K     K    23 
R284           K            5 
G333     E                  5 
V435             I          5 
S447 N     N             N    14 
R461        K               5 
K476  N N N N  N  N N  N  N  N N N  N N N 68 
P510      T       T      T    14 
K512                      R 5 
E514            D           5 
V518 I   I     I  I  I        I  27 
V531 I   G                   5 I/G 
L533    S  M                 5 S/M 
 
Recombinant infectious viruses were created by ligating single-genome-derived full-
length RT amplicons into a wild-type vector (pxxLAI-3D) to assess the phenotype of the 
different RT sequences. Infectious virus was produced and assayed for 3′-azido-ddG 
susceptibility in P4/R5 cells, Table 8. Some clones (36%) were growth defective and could not 
be phenotyped. All of the replication-competent viruses showed similar levels of 3′-azido-ddG 
resistance, with an average fold resistance of 3.6 ± 0.3 (range, 3.2 to 4.0). Of note, bulk cloning 
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of full-length RT amplified from the virus population into pxxLAI-3D produced virus exhibiting 
only 2.2-fold resistance to 3′-azido-ddG. 
 
Table 8: 3'-Azido-ddG susceptibility of recombinant HIV-1 with RT derived from single-genome 
amplifications 
aClone bGenotype cEC50, µM 
dFold 
Resistance
eP 
value 
1 L74V/F77L/V106I/E122K/L214F/R277K/S447N/V518I/V531I 4.5 ± 1.2 3.2 <0.05
2 L74V/F77L/V106I/E122K/L214F/K476N 4.8 ± 1.0 3.4 <0.01
3 L74V/F77L/V106I/L214F/R277K/K476N 5.3 ± 1.8 3.8 <0.05
6 L74V/F77L/V106I/E122K/L214F/S447N/P510T/L533M 5.0 ± 1.6 3.6 <0.05
7 L74V/F77L/E122K/L214F/K476N 4.7 ± 0.7 3.4 <0.01
f10 L74V/F77L/L214F/K476N 5.6 ± 1.5 4.0 <0.01
13 L74V/F77L/L214F/R277K/V435I/P510T/V518I 5.4 ± 0.9 3.8 <0.01
“Bulk” Mixture 2.31 ± 0.01 2.2 <0.05
a Recombinant clones were produced by amplifying full length RT from single genomes or as a 
population (bulk) and cloning into the xxHIVLAI-3D vector for infectious virus production by 
electroporation into MT-2 cells. 
b Genotypes identified by single genome sequencing (Table 7) that are not listed were cloned, but 
determined to be growth defective. 
c Mean ± standard deviation of three experiments. 
d Fold resistance determined against xxHIV-1LAI clone (EC50 = 1.40 ± 0.05 µM)  
e Statistical significance compared to wild-type xxHIV-1LAI-MO determined by two-sample 
Student’s t test. 
f Clone 10 contains a silent G to A transition at nucleotide 423 that encodes for G141 in the HIV-
1xxLAI background. 
 
3.5.4 Selection of HIV-1 resistance to 3′-azido-ddC 
Following 55 passages of HIV-1LAI in increasing concentrations of 3′-azido-ddC, we 
selected virus that was 5.9-fold resistant to 3′-azido-ddC compared to wild-type virus, Figure 19. 
Population sequencing of the entire HIV-1 RT identified the V75I mutation in the DNA 
polymerase domain of the enzyme. When introduced into the backbone of the wild-type HIV-
 65 
1LAI virus by site-directed mutagenesis, the V75I mutation conferred 2.6-fold resistance to 3′-
azido-ddC in MT-2 cells, Table 6. 
 
 
Figure 19: In vitro selection of 3'-azido-ddC and 3'-azido-ddA resistant HIV-1 
Drug-resistant xxHIV-1LAI was selected by serial passage of virus in increasing concentrations of 
3′-azido-ddC (EC50, 86.7 ± 16.9 μM at passage 60) or 3′-azido-ddA (EC50, 3.32 ± 1.06 μM at 
passage 75). Fold resistance and RT genotype were determined as described for Figure 18. 
 
3.5.5 Selection of HIV-1 resistance to 3′-azido-ddA 
After 75 passages of HIV-1LAI in increasing concentrations of 3′-azido-ddA (8.5 μM to 76.5 
μM), we were unable to select for HIV-1 resistance to 3′-azido-ddA, Figure 19. This inability to 
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select for drug-resistant HIV-1 was not due to inefficient metabolism of 3′-azido-ddA to 3′-
azido-ddATP. In Table 9, we show from the quantitative mass spectrometry analyses that 3′-
azido-ddA was metabolized to the active TP form in MT-2 cells in a dose-dependent manner. 
 
Table 9: Levels of 5'-phosphorylated 3'-azido-ddA in MT-2 cells after 4 h of incubation with 3'-azido-ddA 
Extracellular 
3'-azido-ddA (µM) 
aLevel of metabolized  
3’-azido-ddA (pmol/106 cells) 
d Level of metabolized  
3’-azido-ddA (μM) 
 bTP cDP TP DP 
5 0.13 ± 0.02 0.030 ± 0.002 0.240 ± 0.004 0.054 ± 0.003 
12.5 0.22 ± 0.01 0.08 ± 0.01 0.40 ± 0.02 0.15 ± 0.02 
25 0.36 ± 0.05 0.17 ± 0.04 0.66 ± 0.09 0.30 ± 0.07 
50 0.77 ± 0.07 0.25 ± 0.07 1.41 ± 0.14 0.45 ± 0.13 
a Mean ± standard deviation of three experiments. 
b TP is 3'-azido-ddA-5’-triphosphate. 
c DP is 3'-azido-ddA-5’-diphosphate. 
d Mean ± standard deviation of three experiments, determined using average diameter for MT-2 
cells of 12.3 µm. 
3.6 DISCUSSION 
This study clearly shows that the base component of 3′-azido nucleosides strongly influences the 
pattern of resistance mutations in HIV-1 RT that are selected in vitro. Previously, we reported 
that AZT selected for the classical thymidine analog mutations D67N, K70R, and T215F in the 
DNA polymerase domain of the enzyme as well as A371V and Q509L in the connection and 
RNase H domains, respectively [286]. The experimental approach used previously to select 
AZT-resistant HIV-1 was essentially the same as that described here. In contrast to AZT, 3′-
azido-ddG selected for different combinations of L74V, F77L, and L214F in the DNA 
polymerase and K476N and V518I in the RNase H domains of HIV-1 RT, respectively, and 3′-
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azido-ddC selected only the V75I mutation in the DNA polymerase domain. Of note, we have 
been unable to select for 3′-azido-ddA resistance in MT-2 cells (Figure 19) or in primary human 
lymphocytes (data not shown). 
The level of resistance selected in vitro to 3′-azido-ddG is lower than that observed for 
AZT. AZT-resistant HIV-1, selected after 65 passages in MT-2 cells, contained up to 5 
mutations and exhibited >16,200-fold resistance to AZT [286]. By contrast, 3′-azido-ddG-
resistant HIV-1, selected after 90 passages in MT-2 cells, also contained up to 5 mutations, but it 
exhibited only 5.3-fold resistance to 3′-azido-ddG. Interestingly, the virus population selected by 
3′-azido-ddG was exceptionally diverse (Table 7), and the resistant phenotype could not be 
recapitulated through the construction of site-directed mutants that were based on the population 
genotype (Table 6). This finding suggests that population genotype analyses may not be 
definitive when complex mixtures of viruses are present because mutation linkage cannot be 
assessed. Indeed, our phenotypic analyses of single genome sequences provided a more accurate 
characterization of the resistant variants that emerged under 3′-azido-ddG selective pressure 
(Table 8). Importantly, these analyses also demonstrated that no single mutation or set of 
mutations is able to confer sufficient 3′-azido-ddG resistance such that it can become the 
dominant species in the population. 
To date, the phenotypic mechanisms responsible for 3′-azido-ddG and 3′-azido-ddC 
resistance have not been elucidated, although ongoing biochemical studies are addressing this 
issue. The selection of the L74V and F77L mutations (part of the Q151M complex) by 3′-azido-
ddG likely suggests a discrimination mechanism. However, the mechanisms of resistance for 
K476N and V518I are uncertain. Both residues reside in the RNase H domain and may interact 
with the T/P positioning or affect RNase H cleavage activity. Figure 20 shows the locations of 
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these mutations in the crystal structure of HIV-1 RT. Of note, other resistance mutations in the 
connection (e.g., N348I and A360V) and RNase H (e.g., Q509L) domains of HIV-1 RT 
influence drug susceptibility via an indirect RNase H-mediated effect on the NRTI-MP excision 
phenotype [340,352-355]. However, we have also shown that a mutation in the connection 
domain of HIV-1 RT (G333E) directly impacts the enzyme's ability to incorporate 3TC-TP 
[356]. 
 
Figure 20: Locations of 3’-azido-ddG resistance mutations in RT (1HYS) 
The p66 subunit and p51 subunit are shown as ribbon structures in green and pink, respectively. 
The residues are displayed as ball and stick models in yellow. The DNA primer strand and RNA 
template strand are represented in blue and red, respectively. Molecular graphics images were 
produced using POLYVIEW-3D Porollo A, Meller J: Versatile Annotation and Publication 
Quality Visualization of Protein Complexes Using POLYVIEW-3D, BMC Bioinformatics 2007, 
8: 316 and rendered using The PyMOL Molecular Graphics System, Version 1.5.0.4 
Schrödinger, LLC. 
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The V75I mutation identified in the 3′-azido-ddC-resistant HIV-1 has also been observed 
in selection experiments with acyclovir (ACV) and a monophosphorylated prodrug of ACV 
[357,358]. Biochemical studies showed that mutant V75I RT did not alter binding efficiency of 
ACV-triphosphate but increased incorporation of dGTP versus ACV-5′-triphosphate through a 
discrimination mechanism [358]. This suggests that a discrimination mechanism may also be 
responsible for the observed HIV-1 resistance to 3′-azido-ddC. Studies of cross-resistance of the 
V75I mutant in primary activated CD4+ lymphoblasts have shown that V75I increases the EC50 
for FTC, 3TC, ddI, and ABC, does not change the EC50 for TDF or d4T, and causes 
hypersusceptibility to AZT [359]. 
We were unable to select 3′-azido-ddA-resistant HIV-1 in vitro. Virus from passage 75 in 
media containing 3′-azido-ddA concentrations up to 75.6 μM did not show mutations in RT and 
did not exhibit any change in 3′-azido-ddA susceptibility. It is not clear why resistance did not 
emerge and how passaged virus was able to replicate despite high 3′-azido-ddA concentrations. 
We showed that 3′-azido-ddA was efficiently metabolized to the active 5′-triphosphate form in 
MT-2 cells that were used for selection (Table 9). Nevertheless, there may be subsets of cells that 
do not efficiently metabolize 3′-azido-ddA to the active 5′-triphosphate and allow virus to 
replicate without developing resistance. Such a mechanism has been shown in vitro through 
isolation of cell clones that are not protected from HIV-1 infection by AZT [360]. The cell cycle 
can transiently alter the amount of intracellular NRTI-TP or the levels of competing natural 
dNTPs. Cellular resistance, or permanent alterations in NRTI metabolism or uptake, is more 
likely to develop during prolonged exposure of cells to an NRTI [361]. We reduced this latter 
possibility by using new cells at the start of each passage, although the 5- to 7-day duration of 
each passage could have allowed outgrowth of cells with altered NRTI metabolism. An 
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alternative explanation for HIV-1 replication in the presence of 3′-azido-ddA is the emergence 
mutations outside of RT that could increase viral infectivity such that a subset of cells with 
subinhibitory 3′-azido-ddATP concentrations could be infected efficiently. 
In summary, NRTIs with different base structures, but the same 3′-azido-2′,3′-
dideoxyribose sugar, selected for divergent resistance mutations in RT in vitro. These findings 
indicate that the base component of NRTIs can be modified to alter the mechanisms and genetic 
barrier to HIV-1 drug resistance. These insights should prove useful in the synthesis of novel 
NRTIs that pose a high genetic barrier to HIV-1 resistance. 
 71 
4.0  MOLECULAR MECHANISM OF HIV-1 RESISTANCE TO 3’-AZIDO-2’,3’-
DIDEOXYGUANOSINE 
Jeffrey D. Meteer1, Nicolas Sluis-Cremer1, Raymond F. Schinazi2, and John W. Mellors1 
 
1University of Pittsburgh School of Medicine, Department of Medicine, Division of Infectious 
Diseases, Pittsburgh, Pennsylvania 15261 
2Center for AIDS Research, Department of Pediatrics, Emory University School of Medicine, 
and the Veterans Affairs Medical Center, Decatur, Georgia 30033 
 
  
 72 
4.1 PREFACE 
This chapter is adapted from an unpublished study (Meteer, J.D., Sluis-Cremer, N., Schinazi, 
R.F. and Mellors, J.W. 2013. Molecular mechanism of HIV-1 resistance to 3’-azido-2’,3’-
dideoxyguanosine.). The work presented in this chapter is in partial fulfillment of dissertation 
Aim 2. Jeffrey Meteer performed all experimental work in this study. 
4.2 ABSTRACT 
We recently reported that 3’-azido-ddG selected for the L74V, F77L, and L214F mutations in the 
polymerase domain and K476N and V518I mutations in the RNase H domain of HIV-1 RT. In 
this study, we have defined the molecular mechanisms of 3’-azido-ddG resistance by performing 
in-depth biochemical analyses of HIV-1 RT containing mutations 
L74V/F77L/V106I/L214F/R277K/K476N (SGS3). The SGS3 HIV-1 RT was from a single-
genome-derived full-length RT sequence obtained from 3’-azido-ddG resistant HIV-1 selected in 
vitro. We also analyzed two additional constructs that either lacked the L74V mutation (SGS3-
L74V) or the K476N mutation (SGS3-K476N). Pre-steady-state kinetic experiments revealed 
that the L74V mutation allows HIV-1 RT to effectively discriminate between the natural 
nucleotide (dGTP) and 3’-azido-ddG-triphosphate (3’-azido-ddGTP). 3’-azido-ddGTP 
discrimination was primarily driven by a decrease in 3’-azido-ddGTP binding affinity (Kd) and 
not by a decreased rate of incorporation (kpol). The L74V mutation was found to severely impair 
RT’s ability to excise the chain-terminating 3’-azido-ddG-monophosphate (3’-azido-ddGMP) 
moiety. However, the K476N mutation partially restored the enzyme’s ability to excise 3’-azido-
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ddGMP on an RNA/DNA, but not on DNA/DNA, template/primer by selectively decreasing the 
frequency of secondary RNase H cleavage events. Taken together, these data provide strong 
additional evidence that the nucleoside base structure is major determinant of HIV-1 resistance 
to the 3’-azido-2’,3’-dideoxynucleosides. 
4.3 GOAL OF STUDY 
AZT typically selects for TAMs in HIV-1 [199,200]. AZT-MP is also more readily excised by 
HIV-1 RT containing TAMs than are other sugar modified NRTI-MP analogs [362]. Initially, 
Boyer et al. proposed that this was due to the 3’-azido group, which anchored the chain-
terminating AZT-MP in the excision-competent nucleotide-binding site (N-site) and prevented 
its translocation to the excision-incompetent primer-binding site (P-site) [363]. However, we 
reported that the 3’-azido-2’,3’-dideoxypurines retained activity against HIV-1 variants that 
contained multiple TAMs [337,344]. This finding suggested that the 3’-azido-2’,3’-
dideoxynucleoside base was a major determinant of HIV-1 resistance. To further explore this 
hypothesis, we conducted in vitro selection experiments by serial passage of HIV-1LAI in MT-2 
cells in increasing concentrations of 3’-azido-ddG [364]. 3’-Azido-ddG selected for virus that 
was 5.3-fold resistant to the nucleoside compared to wild-type (WT) HIV-1LAI passaged in the 
absence of drug. Population sequencing of the entire reverse transcriptase (RT) gene identified 
L74V, F77L and L214F mutations in the polymerase domain and K476N and V518I mutations 
in the RNase H domain. Under similar conditions, AZT selected for highly resistant virus 
(>16,200-fold over WT) that contained the TAMs D67N, K70R, T215F, A371V and Q509L in 
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RT [286,340]. The selection of divergent mutations indicates that the phenotypic mechanisms 
responsible for resistance between 3’-azido-ddG and AZT are different.  
We therefore investigated the molecular mechanisms of resistance to 3’-azido-ddG by 
performing in-depth biochemical analyses of wild-type and mutants HIV-1 RTs containing 
L74V, L74V/F77L/V106I/L214F/R277K/K476N (SGS3), F77L/V106I/L214F/R277K/K476N 
(SGS3ΔL74V) and L74V/F77L/V106I/L214F/R277K (SGS3ΔK476N). We report that the L74V 
mutation allows HIV-1 RT to effectively discriminate between the natural nucleotide (dGTP) 
and 3’-azido-ddG-triphosphate (3’-azido-ddGTP). We also show that the K476N mutation 
partially restores the enzyme’s ability to excise 3’-azido-ddGMP on an RNA/DNA, but not 
DNA/DNA, template/primer by selectively decreasing the frequency of secondary RNase H 
cleavage events. 
4.4 MATERIALS AND METHODS 
4.4.1 Materials 
AZT-TP and 3’-azido-ddGTP were purchased from Trilink Biotechnologies (San Diego, CA). 
ATP, deoxyribonucleotide triphosphates (dNTPs) and dideoxy nucleoside triphosphates were 
purchased from GE Healthcare (Piscataway, New Jersey, USA), and [γ-32P]-ATP was acquired 
from PerkinElmer Life Sciences (Boston, Massachusetts, USA). RNA and DNA 
oligonucleotides were synthesized by Integrated DNA Technologies (Coralville, Iowa, USA). 
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4.4.2 Cloning, site-directed mutagenesis and purification of HIV-1 RT  
We previously reported that when the L74V, F77L, L214F, K476N and V518I mutations were 
introduced into HIV-1 by site-directed mutagenesis they only conferred ~2.0-fold resistance 
[364]. However, if we generated HIV-1 clones containing single-genome-derived full-length RT 
sequences from the 3’-azido-ddG resistant virus population selected in vitro, the recombinant 
virus yielded higher levels of 3’-azido-ddG resistance (range 3.2 to 4.0-fold) [364]. Therefore, in 
this study we cloned into the p6HRT-PROT prokaryotic expression vector [365] one of these 
single-genome-derived full-length RT sequences (SGS3) that contained 
L74V/F77L/V106I/L214F/R277K/K476N mutations. The contributions of the L74V and K476N 
mutations were studied in the context of SGS3 HIV-1 RT by reverting out the mutations by site-
directed mutagenesis (QuikChange Lightning site-directed mutagenesis kit; Stratagene, La Jolla, 
CA) to generate the F77L/V106I/L214F/R277K/ K476N (SGS3ΔL74V) and 
L74V/F77L/V106I/L214F/R277K (SGS3ΔK476N) enzymes. We also introduced the L74V 
mutation into WT HIV-1LAI RT by site-directed mutagenesis. Full-length sequencing of mutant 
RTs was performed to confirm the presence of the desired mutations and to exclude adventitious 
mutations introduced during mutagenesis.  WT and mutant recombinant HIV-1 RTs were over-
expressed and purified to homogeneity as described previously [365]. RT concentration was 
determined spectrophotometrically at 280nm using an extinction co-efficient (ε280) of 260 450 M-
1 cm-1. 
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4.4.3 Steady-state DNA polymerization by WT & mutant HIV-1 RT 
A 19 nucleotide DNA primer (P19; 5’-TTGTAGCACCATCCAAAGG-3’) annealed to a 36 
nucleotide DNA template (T36; 5’-AGAGCCCCCGAGACCTTTGGATGGTGCTACAAGCT-
3’) was used in these experiments. P19 was 5’-radiolabeled with [γ-32P]-ATP and T4 
polynucleotide kinase, as described previously [233,337,340,366,367]. 5’-32P-labeled P19 was 
then annealed to T36 by adding a 1:1.5 molar ratio of primer to template at 90°C and allowing 
the mixture to slowly cool to ambient room temperature. DNA polymerization was assessed by 
incubating 200 nM WT or mutant HIV-1 RT with 20 nM template/primer (T/P; T36/P19) in 
50mM Tris-HCl (pH 7.5), 50 mM KCl, 10 mM MgCl2. The reaction was initiated by the addition 
of 0.1 or 1 μM mixed dNTPs. After defined incubation periods, aliquots were removed and 
processed as described previously [337,340,366,367]. 
 
4.4.4 Steady-state assays of 3’-azido-ddGTP incorporation and 3’-azido-ddGMP excision 
by WT and mutant HIV-1 RT 
In these assays, we assessed the ability of WT or mutant HIV-1 RT to synthesize full-length 
DNA product on the T36/P19 T/P in the presence of 5 μM 3’-azido-ddGTP and 3 mM ATP. 
Briefly, 200 nM WT or mutant HIV-1 RT was pre-incubated with 20 nM 5’-32P-end-labeled T/P 
in 50mM Tris-HCl (pH 7.5), 50 mM KCl, 10 mM MgCl2. Reactions were initiated by the 
addition of 0.5 μM mixed dNTPs, 5 μM 3’-azido-ddGTP and 3 mM ATP. After defined 
incubation periods, aliquots were removed and processed as described above. 
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4.4.5 Pre-steady-state assays of dGTP or 3’-azido-ddGTP incorporation by WT or 
mutant HIV-1 RT 
A 5’-32P-labeled 20 nucleotide DNA primer (P20; 5’-TCGGGCGCCACTGCTAGAGA-3’) 
annealed to a 52 nucleotide DNA template (T36; 5’-CTCAGACCCTTTTAGTCAGAATG 
GAAAATCTCTAGCAGTGGCGCCCGAACAG-3’) was used in these experiments. A Kintek 
RQF-3 instrument (Kintek Corporation, Clarence, PA) was used for pre-steady state experiments 
with reaction times ranging from 5 ms to 3 min. The typical experiment was performed at 37°C 
in 50 mM Tris-HCl (pH 7.5) containing 50 mM KCl, 10 mM MgCl2 and varying concentrations 
of dGTP or 3’-azido-ddGTP (0.5 to 10 μM). All concentrations reported refer to the final 
concentrations after mixing. WT or mutant HIV-1 RT (200 nM) was pre-incubated with 20 nM 
T/P, prior to rapid mixing with nucleotide and divalent metal ions to initiate the reaction that was 
quenched with 50 mM EDTA. Products were resolved and analyzed, as described previously 
[337,367]. Data were fitted by nonlinear regression with Sigma Plot software (Systat Software, 
Inc., San Jose, CA) using the appropriate equations [368]. The apparent burst rate constant (kobs) 
for each particular concentration of dGTP or 3’-azido-ddGTP was determined by fitting the time 
courses for the formation of product using the following equation: product= A[1 − exp(−kobst)], 
where A represents the burst amplitude. The turnover number (kpol) and apparent dissociation 
constant for the nucleotide analog (Kd) were then obtained by plotting the apparent catalytic rates 
(kobs) against nucleotide analog concentrations and fitting the data with the following hyperbolic 
equation: kobs = (kpol[dNTP])/([dNTP] + Kd). Catalytic efficiency was calculated as the ratio of 
turnover number over dissociation constant (kpol/Kd). Selectivity for natural dGTP versus 3’-
azido-ddGTP was calculated as the ratio of catalytic efficiency of dGTP over that of the analog 
(kpol/Kd)dGTP/(kpol/Kd)3’-azido-ddGTP. 
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 4.4.6 Steady-state excision of 3’-azido-ddGMP by WT or mutant HIV-1 RT 
A 23 nucleotide primer ( P23; 5’-TTGTAGCACCATCCAAAGGTCTC-3’) was 5’-end labeled 
with [γ-32P]-ATP, chain-terminated with 3’-azido-ddGMP and annealed to a DNA (T36) or RNA 
(T36RNA; 5’-rCrArGrArGrCrCrCrCrCrGrArGrArCrCrUrUrUrGrGrArUrGrGrUrG 
rCrUrArCrArArGrCrU-3’) template, as described previously [337,344,367]. 200 nM WT or 
mutant HIV-1 RT was pre-incubated with 20 nM T/P in 50mM Tris-HCl (pH 7.5), 50 mM KCl, 
10 mM MgCl2. Reactions were initiated by the addition of 2 μM dGTP, 40 μM ddCTP and 3 
mM ATP. After defined incubation periods, aliquots were removed and processed as described 
above.  
 
4.4.7 Assay for RT RNase H activity 
WT and mutant RT RNase H activity was evaluated using the same 3’-azido-ddGMP chain-
terminated RNA/DNA T/P substrate described above, except the 5′-end of the RNA was 32P-end-
labelled. Assays were carried out using 20 nM TRNA/P3’-azido-ddG, 3 mM ATP and 10 mM MgCl2 
in a buffer containing 50 mM Tris-HCl (pH 7.5) and 50 mM KCl. Reactions were initiated by the 
addition of 200 nM WT or mutant HIV-1 RT. Aliquots were removed, quenched at varying 
times, and analysed as described above. 
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4.5 RESULTS 
4.5.1 DNA polymerase activity of WT and mutant HIV-1 RT 
As described in the Materials and Methods, we cloned a single-genome-derived full-length RT 
sequence (SGS3) derived from a 3’-azido-ddG resistant virus population selected in vitro [364] 
that contained the L74V/F77L/V106I/L214F/R277K/K476N mutations into the p6HRT-PROT 
prokaryotic expression vector. We also generated 2 additional constructs that either lacked either 
the L74V mutation (SGS3ΔL74V) or the K476N mutation (SGS3ΔK476N). Each of the mutant 
enzymes was purified to homogeneity and analyzed for DNA-dependent DNA polymerase 
activity using either 0.1 μM or 1.0 μM dNTP. The DNA polymerization activity of all three 
mutant RTs was compromised compared to the WT enzyme, Figure 21. Specifically, the mutant 
RTs generated less full-length DNA product and there was an increase in the accumulation of 
shorter DNA products compared to the WT enzyme. We also assessed DNA polymerization by 
SGS3 and WT HIV-1 RT under processive conditions. The results in Figure 22 show that SGS3 
RT is less processive than the WT enzyme at low (1.0 μM) and high (10.0 μM) concentrations of 
dNTP. 
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 Figure 21: DNA-dependent DNA polymerase activities of WT, SGS3, SGS3ΔL47V and SGS3ΔK476N HIV-1 
RT 
Representative autoradiogram of the DNA-dependent DNA polymerase activity of WT, SGS3, 
SGS3ΔL74V and SGS3ΔK476N HIV-1 RT under steady-state assay conditions. Reactions were 
carried out at 0.1 and 1.0 μM dNTP. Reactions times were 0, 1, 2, 3, 4 and 5 min. 
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 Figure 22: DNA-dependent DNA polymerase activities of WT and mutant HIV-1 RT under processive 
conditions 
Representative autoradiogram of the DNA-dependent DNA polymerase activity of WT, SGS3, 
SGS3ΔL74V and SGS3ΔK476N HIV-1 RT under processive steady-state assay conditions. 
Reactions were carried out at 1.0 and 10 μM dNTP. Unlabeled T36/P19 T/P was used as a trap at 
200 nM. Reaction times were 0, 30, 60, 90, 120 and 180 sec for 1.0 μM dNTP or 0, 15, 30, 60, 
90 and 120 sec for 10 μM dNTP. 
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4.5.2 3’-azido-ddGTP incorporation and 3’-azido-ddGMP excision activity of WT and 
mutant HIV-1 RT 
During HIV-1 replication there are multiple opportunities for RT to incorporate and excise 
nucleotide analogs. As such, we initially assessed the ability of WT and mutant HIV-1 RT to 
synthesize full-length DNA product in the presence of 3’-azido-ddGTP and ATP under steady-
state assay conditions. Figure 23 shows that in the presence of 5 μM 3’-azido-ddGTP and 3 mM 
ATP, the SGS3 and SGS3ΔK476N RTs synthesized significantly greater amounts of full-length 
DNA than did the WT or SGS3ΔL74V enzymes. This increase in DNA product formation by 
these RTs appeared to be driven by a decrease in the frequency of 3’-azido-ddGMP chain-
termination. Of note, this assay was carried-out over a long time period (5-90 min) to allow for 
the enzyme to excise the chain-terminating 3’-azido-ddGMP moiety. In this regard, there was no 
evidence of a decrease in chain-termination through excision at any of the sites at which 3’-
azido-ddGTP had been incorporated. Taken together, this data suggested that 3’-azido-ddG 
resistance was driven by a discrimination phenotype mediated by the L74V mutation.
 Figure 23: 3'-Azido-ddGTP incorporation and 3'-azido-ddGMP excision activity 
Representative autoradiogram of the DNA-dependent DNA polymerase activity of WT, SGS3, 
SGS3ΔL74V and SGS3ΔK476N HIV-1 RT in the presence of 5 μM 3’-azido-ddGTP and 3 mM 
ATP under steady-state assay conditions. Reaction times were 0, 5, 10, 15, 30, 45, 60 and 90 
min. 
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4.5.3 Pre-steady-state incorporation of dGTP and 3’-azido-ddGTP by WT and mutant 
HIV-1 RT 
Pre-steady state kinetic analyses were carried out to elucidate the interactions of dGTP and 3’-
azido-ddGTP with the polymerase active sites of WT and SGS3 HIV-1 RT, Table 10.  These 
experiments defined the maximum rates of nucleotide incorporation (kpol), the nucleotide 
dissociation constants (Kd), and the catalytic efficiencies of incorporation (kpol/Kd). The kpol/Kd 
values for the incorporation of dGTP by WT or SGS3 HIV-1 RT were essentially identical, 
suggesting that the L74V/F77L/V106I/L214F/R277K/K476N mutations do not adversely affect 
single nucleotide turn-over events. The selectivity of RT, which is defined as (kpol/Kd)dGTP/ 
(kpol/Kd)3’-azido-ddGTP, is an indication of the ability of the WT or SGS RT to discriminate between 
dGTP and 3’-azido-ddGTP. As reported previously, the WT enzyme cannot discriminate 
between dGTP and 3’-azido-ddGTP (selectivity < 1) [337,344]. By contrast, the mutations in 
SGS3 RT independently increased the selectivity of the enzyme for the natural substrate versus 
3’-azido-ddGTP, Table 10. The observed 3’-azido-ddGTP resistance of SGS3 RT could 
primarily be attributed to a decrease in Kd and not a decrease in kpol. Unfortunately, we were 
unable to purify sufficient quantities of the SGS3ΔL74V and SGS3ΔK476N RTs to perform pre-
steady-state kinetic assays. Therefore, we also carried out analyses to elucidate the interactions 
of dGTP and 3’-azido-ddGTP with the polymerase active site of L74V HIV-1 RT, Table 10. 
Similar to SGS3 RT, the L74V enzyme could effectively discriminate between dGTP and 3’-
azido-ddGTP by decreasing the affinity of the nucleotide analog for DNA polymerase active site. 
Of note, the calculated 3’-azido-ddGTP fold-resistance (Fold-R) values for SGS3 and L74V RT 
were similar. 
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Table 10: Pre-steady-state kinetic values for incorporation of dGTP and 3'-azido-2',3'-ddG 
Nucleotide kpol (s-1) Kd (µM) kpol/kd (µM-1s-1) aSelectivity bFold-R 
WT HIV-1 RT 
dGTP c18.1 ± 6.7  1.3 ± 1.2 13.98 - 
3'-azido-ddGTP  18.2 ± 7.6 0.7 ± 0.1 26.47 0.53 1 
SGS3 HIV-1 RT 
dGTP  20.1 ± 1.8 1.8 ± 0.9 11.2 - 
3'-azido-ddGTP  20.0 ± 4.6 3.6 ± 1.7 5.6 1.99 3.75 
L74V HIV-1 RT 
dGTP 21.5 ± 11.6 0.6 ± 0.3 38.49 - 
3'-azido-ddGTP 28.2 ± 11.3 1.2 ± 0.6 23.57 1.63 3.1 
a Selectivity is (kpol/Kd)dGTP/(kpol/Kd)3’-azido-ddGTP. 
b Resistance (n-fold) is selectivitymutant/selectivityWT. 
c Data are the mean ± S.D. determined from at least three independent experiments. 
 
4.5.4 Excision of 3’-azido-ddGMP by WT and mutant HIV-1 RT 
Prior studies have shown that the L74V mutation significantly attenuates RTs ability to excise 
the chain-terminating NRTI-MP [239,369]. However, we recently demonstrated that the N348I 
mutation in the connection domain of RT could augment the excision activity of the L74V 
enzyme by selectively decreasing the frequency of secondary RNase H cleavages that reduce the 
overall efficiency of the excision reaction [370]. Therefore, we next examined the ability of WT, 
SGS3, SGS3ΔL74V and SGS3ΔK476N HIV-1 RT to excise 3’-azido-ddGMP and rescue DNA 
synthesis from chain-terminated DNA/DNA and RNA/DNA T/Ps, Figure 24. An excision-
competent RT containing the TAMs D67N/K70R/T215F/K219Q (AZTR) was also included as a 
control in these experiments. On the DNA/DNA T/P substrate, the SGS3 and SGS3ΔK476N RTs 
were significantly less efficient in excising 3’-azido-ddGMP than was the WT enzyme. The 
ATP-mediated excision activity of the SGS3ΔL74V RT was similar to that of the WT enzyme. 
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These observations are consistent with the L74V mutation significantly reducing RTs ability to 
excise chain-terminating nucleotide analogs. In contrast, on the RNA/DNA T/P substrate, the 
ATP-mediated excision activity of SGS3 RT was comparable to that of the WT enzyme.  
Reversion of L74V to the WT codon (i.e. SGS3ΔL74V) significantly increased the enzyme’s 
ability to excise 3’-azido-ddGMP suggesting that the F77L/V106I/L214F/R277K/K476N 
mutations contribute to an excision phenotype on an RNA/DNA, but not DNA/DNA, T/P. 
Reversion of K476N to the WT codon (i.e. SGS3ΔK476N RT) almost completely abolished RTs 
ability to excise 3’-azido-ddGMP indicating that the K476N mutation counteracts the negative 
effect of L74 on excision. 
 
 
Figure 24: ATP-mediated excision of 3'-azido-ddGP and rescue of DNA synthesis by HIV-1 RT on chain 
terminated T/P 
Reaction performed using T/Ps with the same sequence. A. DNA/DNA T/P substrate and B. 
RNA/DNA T/P substrate. Data are the mean ± standard deviation determined from at least 3 
independent experiments. 
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We previously delineated the relationship between AZT-MP excision efficiency and 
RNase H activity on a RNA/DNA T/P substrate that was essentially identical to the one used in 
these experiments [340,343]. These studies showed that the primary polymerase-dependent 
RNase H cleavages do not impact the enzyme’s excision efficiency, but polymerase-independent 
RNase H cleavages that reduce the RNA/DNA duplex length to less than 12 nucleotides abolish 
the excision activity. In light of this, we next evaluated the RNase H activity of the WT and 
mutant RTs that occurred during the ATP-mediated excision reactions. The data in Figure.25 
shows that the SGS3 and SGS3ΔL74V RTs carryout less secondary RNase H cleavages. As a 
result, there is prolonged preservation of T/P substrates with duplex lengths of 15-18 nucleotides. 
As described above, RT can efficiently excise a chain-terminating NRTI-MP from these 
substrates [340,343]. In contrast, these T/P substrates (with duplex lengths of 15-18 nucleotides) 
are not preserved in reactions carried out by the WT and SGS3ΔK476N RTs. 
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Figure 25: Representative autoradiogram of the RNase H cleavage activity that occurs during the 3'-azido-
ddGMP excision reaction 
No RNA degradation was observed in the absence of RT or for RNase H null D443N. The 
reaction times were 10, 5 15, 30, 45, 60, 90 and 120 min. 
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4.6 DISCUSSION 
In this study we show that the L74V/F77L/V106I/L214F/R277K/K476N mutations in HIV-1 RT 
confer 3’-azido-ddG resistance primarily through discrimination with some contribution from 
excision. The NRTI-TP discrimination resistance phenotype was mediated by the L74V mutation 
in HIV-1 RT, whereas the NRTI-MP excision phenotype was primarily mediated by the K476N 
mutation. We were unable to clarify the relative contributions of the F77L, V106I, L214F and 
R277K in HIV-1 RT to 3’-azido-ddG resistance. 
Our kinetic data shows that the L74V mutation allows HIV-1 RT to effectively 
discriminate between dGTP and 3’-azido-ddGTP by selectively decreasing the nucleotide 
analog’s binding affinity (i.e. Kd). L74V is selected by other purine analogs including didanosine 
and abacavir [242,371], and a prior pre-steady-state kinetic study reported that the L74V 
mutation allows RT to discriminate between dATP and ddATP [372]. Interestingly, L74V in 
HIV-1 RT confers ~ 3-fold resistance to 3’-azido-ddGTP (Table 10), but HIV-1 containing the 
L74V mutation remains sensitive to inhibition by 3’-azido-ddG [344]. In this regard, it has been 
shown that the K65R mutation in HIV-1 RT allows the enzyme to discriminate between TTP and 
AZT-TP [366,373]. Like L74V, K65R significantly decreases the ATP-mediated excision 
activity of the enzyme, and it was proposed that the combination of these opposing mechanisms 
results in the increased susceptibility of HIV-1 containing the K65R mutation to AZT [373]. In 
this study, we show that HIV-1 has compensated for the decreased excision activity of L74V RT 
through the gain of additional mutations, particularly K476N, that augments the enzyme’s ability 
unblock the chain-terminating 3’-azido-ddGMP moiety on RNA/DNA T/P substrates. Indeed, we 
found that K476N restored the enzyme’s ability to excise 3’-azido-ddGMP on an RNA/DNA, but 
not DNA/DNA, T/P by selectively decreasing the frequency of secondary RNase H cleavage 
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events that preserved excision-competent RNA/DNA T/P substrates with duplex lengths ranging 
from 15-18 nucleotides. Taken together, these findings suggest that K476N, like the A360V, 
N348I and Q509L mutations, impacts the efficiency of the excision reaction by an RNase H-
dependent mechanism [340,352,355,374].   
In Figure 21, we show that SGS3 RT has reduced DNA polymerase activity compared to 
the WT enzyme. However, the pre-steady-state kinetic analyses demonstrated that the catalytic 
efficiency ratios (i.e. kpol/Kd) for SGS3 and WT HIV-1 RT were comparable. These data suggest 
that the L74V/F77L/V106I/L214F/R277K/K476N mutations do not directly impact the DNA 
polymerase active site of HIV-1 RT. Instead, we show that the decrease in DNA polymerase 
activity of SGS3 RT under steady-state assay conditions is likely due to decreased processivity, 
Figure 22. A decrease in the in vitro processivity of L74V HIV-1 RT has been documented 
previously [372,375]. 
The level of resistance that HIV-1 achieves to 3’-azido-ddG after in vitro selection is 
modest (3- to 4-fold) and requires multiple resistance mutations, including L74V that markedly 
reduce nucleotide excision. This L74V-mediated reduction in excision was only partial reversed 
by K476N in the RNase H domain, suggesting that there are molecular constraints on HIV-1 RT 
such that it does not readily evolve high-level resistance to 3’-azido-ddG through discrimination 
and excision mechanisms, either alone or in combination. The data presented in this report 
provide genetic and biochemical insights into the favorable activity profile of 3’-azido-ddG 
against NRTI-resistant virus.  
In conclusion, our analyses reveal that HIV-1 resistance to 3’-azido-ddG is mediated by 
both the NRTI-TP discrimination and NRTI-MP excision phenotypes. By comparison, AZT 
selects for TAMs in HIV-1 that confer resistance exclusively via the NRTI-MP excision 
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phenotype. As such, these data strongly reinforce the thesis that the nucleoside base structure is 
major determinant of HIV-1 resistance to the 3’-azido-2’,3’-dideoxynucleosides and that further 
optimization of base structure is possible to enhance the activity and resistance profile of 3’-
azido-2’,3’-dideoxynucleosides. 
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5.0  FINAL SUMMARY AND FUTURE DIRECTIONS 
There are limitations of the currently available NRTI including development of resistance, cross-
resistance between inhibitors and high levels of toxicity. These issues restrict the usefulness of 
NRTI in HIV-1 therapy. This is compounded by a gap in knowledge for the rationale 
development of new NRTI inhibitors. Specifically, it is not known what structural components of 
NRTI are the determining factors for activity, resistance and toxicity. This thesis aims to 
delineate these structure-activity-resistance relationships using 3’-azido-2’,3’-dideoxynucleoside 
analogs. 
This thesis adds to the field of drug resistance, but a greater understanding of these 
observations in the context of current HIV-1 therapy is necessary to evaluate the selected 
resistance and mechanisms by which 3’-azido-2’,3’-dideoxynucleosides inhibit HIV-1 RT in 
order to develop novel and potent antiretrovirals. 
5.1 SUMMARY OF 3’-AZIDO-2’,3’-DIDEOXYNUCLEOSIDE-SELECTED 
RESISTANCE IN HIV-1 
We have described that NRTIs with different base structures, but the same 3′-azido-2′,3′-
dideoxyribose sugar, selected for divergent resistance mutations in RT in vitro. In addition, 3’-
azido-2’,3’-ddG was only able to select a very low level of resistance while maintaining activity 
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against TAM containing viruses. Not surprisingly, 3’-azido-ddG did not select for TAMs, but 
instead a group of mutations unknown to be selected by any other FDA-approved compound. 
Furthermore, it was discovered that 3’-azido-ddG selected for a diverse population of mutants 
with different mutations determined by single genome sequencing. Conversely, 3’-azido-ddC 
selected the single RT mutation V75I and 3’-azido-ddA selected no RT mutations. Interestingly, 
the EC50 value of 3’-azido-ddA did not change during the course of the selection, but 
nevertheless virus was able to replicate through increasingly high concentrations of inhibitor. We 
were unable to determine the mechanism of this 3’-azido-ddA-resistance phenotype. 
These findings support the hypothesis that the base component of NRTIs are important 
factors in determining their antiretroviral activity and suggests that NRTI base structures, 
particularly guanosine, could be modified to alter the mechanisms and genetic barriers to HIV-1 
drug resistance. These insights should guide the synthesis of novel NRTIs that pose a high 
genetic barrier to HIV-1 resistance and are active against HIV-1 RT harboring drug-resistance 
mutations to other inhibitors. 
5.2 SUMMARY OF BIOCHEMICAL MECHANISMS OF RESISTANCE TO 3’-
AZIDO-ddG BY HIV-1 
The molecular mechanism of 3’-azido-ddG-resistance by selected mutations was 
determined biochemically. Interestingly, HIV-1 only achieves a modest level of resistance to 3’-
azido-ddG after extensive in vitro selection and requires the accumulation of multiple resistance 
mutations, including L74V that markedly reduces nucleotide excision activity. This L74V-
mediated reduction in excision was only partial reversed by K476N in the RNase H domain, 
 94 
suggesting that there are molecular constraints on HIV-1 RT such that it does not readily evolve 
high-level resistance to 3’-azido-ddG through discrimination and excision mechanisms, either 
alone or in combination. We have presented genetic and biochemical insights into the favorable 
activity profile of 3’-azido-ddG against NRTI-resistant virus. 
In conclusion, our analyses reveal that HIV-1 resistance to 3’-azido-ddG is mediated by a 
dual mechanism with both NRTI-TP discrimination and NRTI-MP excision phenotypes. By 
comparison, the thymine analog AZT selects for TAMs in HIV-1 RT that confer resistance 
exclusively through the NRTI-MP excision phenotype. These data strongly reinforce the 
hypothesis that the nucleoside base structure is major determinant of HIV-1 resistance to the 3’-
azido-2’,3’-dideoxynucleosides and that further optimization of base structure is possible to 
enhance the activity and resistance profile of 3’-azido-2’,3’-dideoxynucleosides. 
5.3 FUTURE DIRECTIONS OF 3’-AZIDO-2’,3’-DIDEOXYNUCLEOSIDE 
ANTIRETROVIRAL RESEARCH 
5.3.1 Limitations of in vitro selections and additional experiments 
A major limitation of the in vitro selection experiments described in Chapter 2 is that each was 
only performed once, n = 1, due to the length of time required for each selection and the cost and 
space required. In retrospect, performing selections in parallel would have been more ideal. It is 
currently not known if different mutation patterns could promote additional resistance to these 
3’-azido-2’,3’-dideoxyucleoside analog inhibitors. It is highly suggested that these experiments 
be repeated to determine other possible outcomes. Additionally, it would be prudent to also 
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passage virus other than wild-type to determine how the input virus affects the selected 
resistance. Key mutations, such as L74V, could be studied in depth using this method. 
Additionally, it would be interesting to determine the reversion of mutations following passage 
in the absence of inhibitor. Do the mutations simply disappear over time, or are they maintained 
over many viral replications? 
Another concern is the level of inhibitor present in media and cells over time. The current 
protocol used here likely has a time dependent decrease in concentration of inhibitor. This drop 
in inhibitor concentration allows some low level of viral replication to occur, which is important 
to allow the virus to accumulate random mutations and evolve resistance phenotypes. 
The process of selecting resistant virus described here is tedious and stochastic. It would 
be interesting to initiate a selection by starting with a diverse population of mutations instead of a 
clonal virus. Susceptible viruses would immediately be blocked from replicating and would be 
quickly eliminated. Resistant viruses would be able to become dominant quickly because their 
resistance mutations would already be preexisting. The key to the success of this experiment of 
rapid selection is creating a controlled, random mutagenesis library of viruses to obtain all 
possible base substitutions isolated in the RT gene. 
5.3.2 Modifications of base structure 
We have provided evidence that the base structure is a determinant of antiviral activity. For 
example, 3’-azido-2’,3’-dideoxypurine analogs are potent inhibitors of TAM containing RT. 
However, it is hypothesized that additional modifications of the natural purine base structures, 
Figure 26, could enhance activity, metabolism and cytotoxicity. There have been multiple studies 
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by our group and others that indicate that this rational drug design approach is an efficient 
method to convert antiretroviral lead compounds into potent inhibitors [376-383]. 
 
Figure 26: Matrix of proposed heterobase-modified 3'-azido-2',3'-dideoxypurine analogs 
All NRTI are administered as prodrugs that must be metabolized into triphosphate forms 
to be active inhibitors. The first phosphorylation step is often rate limiting and can potentially be 
eliminated by administering the NRTI as an NRTI-MP, either as a phosphate or phosphonate, 
like TDF. This can increase the amount of intracellular active metabolite present and effectively 
enhance potency. 
Of note, there are only three FDA-approved purine-base NRTI currently available: ddI, 
TDF and ABC. These inhibitors have greatly enhanced the antiretroviral arsenal available for 
combination HIV-1 therapy, but are plagued with several undesirable attributes. They are all 
vulnerable to selected resistance and cross-resistance, ABC is associated with a hypersensitivity 
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reaction in a small percentage of the population, and TDF is incompatible with ddI and the PI 
atazanavir [384-387]. The base-modified 3’-azido-2’,3’-dideoxypurine analogs may be able to 
circumvent these problems and provide additional therapeutic compounds to combat an ever 
changing disease. 
5.3.3 HIV-1 subtypes and antiretroviral inhibitors 
There is a major discrepancy in most HIV-1 research because subtype B is the most prominent 
subtype in industrialized nations and used in most research studies, however subtype C is most 
prevalent globally [17]. The effects of current treatments on individuals infected with non-
subtype B viruses are not clear. Some evidence suggests that the different subtypes may respond 
differently to FDA-approved therapeutics [388-390]. This is compounded by non-B subtype 
polymorphisms that are often observed as selected secondary resistance mutations in subtype B 
[388,391,392]. There are critical distinctions between the different subtypes that may require 
different antiretrovirals for effective therapeutics. For example, subtype D clinical isolates have 
been observed in vitro to have reduced drug sensitivity to AZT and 3TC due to its rapid growth 
kinetics unmatched by subtypes A, B, C and E [393]. Unfortunately, these NRTI are important in 
resource limiting settings where subtype D is most prevalent. These observations imply that the 
current laboratory standard HIV-1 subtype B may not be the most appropriate model for the 
study of all HIV-1 resistance development. Additionally, it would be advantageous to know the 
subtype before initiation of therapy to avoid known inhibitors with subtype-inherent resistance. 
However, the expense and complexity of genotyping restricts the practicality of this option and 
the limited availability of alternative regimens affords little variation in treatment choices based 
on genotyping results. There is a gap in the research of non-subtype B antiretrovirals that 
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highlights the need for the development of novel, potent inhibitors specifically directed for 
activity to towards these viruses. 
5.3.4 HIV-1 resistance to 3’-azido-ddA 
During in vitro selection experiments, we were able to passage virus through media containing 
increasing concentrations of 3’-azido-ddA well above the EC50. However, there were no 
mutations selected in the gene of RT and accordingly there was no increase in observed EC50 by 
the selected virus. There are several possibilities for this phenomenon. First, the 3’-azido-ddA 
resistance may be due to a mechanism in which the virus is able to efficiently infect cells that are 
not actively metabolizing the inhibitor into the triphosphate form. This may arise from the 
accumulation of mutations outside of RT, particularly in Env, that would increase the infectivity 
of the virus in order to increase the probability of infecting the small percentage of these cells. 
Additionally, even if cells are metabolizing the pro-drug into the active compound, it is possible 
that the intracellular distribution of the active inhibitor-triphosphate does not coincide with the 
physical location of the reverse transcriptase complex in the cytoplasm. 
It will be critical to sequence the entire genome of this passaged virus to look for 
mutations outside of RT that could potentially contribute to this effect. Additionally, it would be 
advantageous to identify which cells are not metabolizing the drug and why. It is likely that 
during certain parts of the cell cycle, the cells are not expressing the kinases or phosphoryl 
transferases required to metabolize the triphosphate, and thus these particular cells are 
susceptible to infection. 
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5.3.5 Sequencing single-genomes of clinical isolates 
The genotype of the virus has a direct impact on the resistance to antiretrovirals and many viral 
phenotypes can be inferred from sequences alone [394-397]. Our selection of 3’-azido-ddG-
resistant HIV-1 resulted in a complex population of viruses with mixed genotypes [364]. 
Standard population sequencing of bulk virus was insufficient to sample the RT genome 
sequences because the linkage of mutations within each genome was not consistent. Single 
genome sequencing was required to determine the actual full-length genotypes of individual viral 
genomic RT. It would be interesting to perform this on patient isolates to determine the dynamics 
of resistance mutation selection in vivo. 
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APPENDIX A 
A.1 SEQUENCE OF HIV-1xxLAI-MO RT 
The complete sequence of wild-type HIV-1xxLAI-MO RT is provided in this appendix. The 
positions of the unique sites for restriction endonuclease cleavage by XmaI, MluI, XbaI and 
NgoMIV have been noted. Additionally, the codons of all major selected mutations in this thesis 
have been highlighted (yellow for 3’-azido-ddG-associated, blue for 3’-azido-ddC-associated) 
for reference. The forward sequencing primers used are marked in green.  
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XmaI 
3 6 9 12 15 18 21 24 27 30 33 36 39 42 45 48 
nt CCC ATT AGT CCT ATT GAA ACT GTA CCA GTA AAA TTA AAG CCC GGG ATG 
AA Pro Ile Ser Pro Ile Glu Thr Val Pro Val Lys Leu Lys Pro Gly Met 
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 
51 54 57 60 63 66 69 72 75 78 81 84 87 90 93 96 
nt GAT GGC CCA AAA GTT AAA CAA TGG CCA TTG ACA GAA GAA AAA ATA AAA 
AA Asp Gly Pro Lys Val Lys Gln Trp Pro Leu Thr Glu Glu Lys Ile Lys 
17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 
99 102 105 108 111 114 117 120 123 126 129 132 135 138 141 144 
nt GCA TTA GTA GAA ATT TGT ACA GAA ATG GAA AAG GAA GGG AAA ATT TCA 
AA Ala Leu Val Glu Ile Cys Thr Glu Met Glu Lys Glu Gly Lys Ile Ser 
33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 
147 150 153 156 159 162 165 168 171 174 177 180 183 186 189 192 
nt AAA ATT GGG CCT GAA AAT CCA TAC AAT ACT CCA GTA TTT GCC ATA AAG 
AA Lys Ile Gly Pro Glu Sn Pro Tyr Ssn Thr Pro Val Phe Ala Ile Lys 
49 50 51 52 53 54 55 56 57 58 59 60 61 62 63 64 
195 198 201 204 207 210 213 216 219 222 225 228 231 234 237 240 
nt AAA AAA GAC AGT ACT AAA TGG AGA AAA TTA GTA GAT TTC AGA GAA CTT 
AA Lys Lys Asp ser Thr Lys Trp Arg Lys Leu Val Asp Phe Arg Glu Leu 
65 66 67 68 69 70 71 72 73 74 75 76 77 78 79 80 
243 246 249 252 255 258 261 264 267 270 273 276 279 282 285 288 
nt AAT AAG AGA ACT CAA GAC TTC TGG GAA GTT CAA TTA GGA ATA CCA CAT 
AA Asn Lys Arg Thr Gln Asp Phe Trp Glu Val Gln Leu Gly Ile Pro His 
81 82 83 84 85 86 87 88 89 90 91 92 93 94 95 96 
291 294 297 300 303 306 309 312 315 318 321 324 327 330 333 336 
nt CCC GCA GGG TTA AAA AAG AAA AAA TCA GTA ACA GTA CTG GAT GTG GGT 
AA Pro Ala gly Leu Lys Lys Lys Lys Ser Val Thr Val Leu Asp Val Gly 
97 98 99 100 101 102 103 104 105 106 107 108 109 110 111 112 
RTS2  
339 342 345 348 351 354 357 360 363 366 369 372 375 378 381 384 
nt GAT GCA TAT TTT TCA GTT CCC TTA GAT GAA GAC TTC AGG AAG TAT ACT 
AA Asp Ala Tyr Phe Ser Val Pro Leu Asp Glu Asp Phe Arg Lys Tyr Thr 
113 114 115 116 117 118 119 120 121 122 123 124 125 126 127 128 
387 390 393 396 399 402 405 408 411 414 417 420 423 426 429 432 
nt GCA TTT ACC ATA CCT AGT ATA AAC AAT GAG ACA CCA GGG ATT AGA TAT 
AA Ala Phe Thr Ile Pro Ser Ile Asn Asn Glu Thr Pro Gly Ile Arg Tyr 
129 130 131 132 133 134 135 136 137 138 139 140 141 142 143 144 
435 438 441 444 447 450 453 456 459 462 465 468 471 474 477 480 
nt CAG TAC AAT GTG CTT CCA CAG GGA TGG AAA GGA TCA CCA GCA ATA TTC 
AA Gln Tyr Asn Val Leu Pro Gln Gly Trp Lys Gly Ser Pro Ala Ile Phe 
145 146 147 148 149 150 151 152 153 154 155 156 157 158 159 160 
483 486 489 492 495 498 501 504 507 510 513 516 519 522 525 528 
nt CAA AGT AGC ATG ACA AAA ATC TTA GAG CCT TTT AGA AAA CAA AAT CCA 
AA Gln Ser Ser Met Thr Lys Ile Leu Glu Pro Phe Arg Lys Gln Asn Pro 
161 162 163 164 165 166 167 168 169 170 171 172 173 174 175 176 
531 534 537 540 543 546 549 552 555 558 561 564 567 570 573 576 
nt GAC ATA GTT ATC TAT CAA TAC ATG GAT GAT TTG TAT GTA GGA TCT GAC 
AA Asp Ile Val Ile Tyr Gln Try Met Asp Asp Leu Try Val Gly Ser Asp 
177 178 179 180 181 182 183 184 185 186 187 188 189 190 191 192 
 
  
 102 
579 582 585 588 591 594 597 600 603 606 609 612 615 618 621 624 
nt TTA GAA ATA GGG CAG CAT AGA ACA AAA ATA GAG GAG CTG AGA CAA CAT 
AA Leu Glu Ile Gly Gln His Arg Thr Lys Ile Glu Glu Leu Arg Gln His 
193 194 195 196 197 198 199 200 201 202 203 204 205 206 207 208 
627 630 633 636 639 642 645 648 651 654 657 660 663 666 669 672 
nt CTG TTG AGG TGG GGA CTT ACC ACA CCA GAC AAA AAA CAT CAG AAA GAA 
AA Leu Leu Arg Trp Gly Leu Thr Thr Pro Asp Lys Lys His Gln Lys Glu 
209 210 211 212 213 214 215 216 217 218 219 220 221 222 223 224 
675 678 681 684 687 690 693 696 699 702 705 708 711 714 717 720 
nt CCT CCA TTC CTT TGG ATG GGT TAT GAA CTC CAT CCT GAT AAA TGG ACA 
AA Pro Pro Phe Leu Trp Met Gly Tyr Glu Leu His Pro Asp Lys Trp Thr 
225 226 227 228 229 230 231 232 233 234 235 236 237 238 239 240 
723 726 729 732 735 738 741 744 747 750 753 756 759 762 765 768 
nt GTA CAG CCT ATA GTG CTG CCA GAA AAA GAC AGC TGG ACT GTC AAT GAC 
AA Val Gln Pro Ile Val Leu Pro Glu Lys Asp Ser Trp Thr Val Asn asp 
241 242 243 244 245 246 247 248 249 250 251 252 253 254 255 256 
771 774 777 780 783 786 789 792 795 798 801 804 807 810 813 816 
nt ATA CAG AAG TTA GTG GGA AAA TTG AAT TGG GCA AGT CAG ATT TAC CCA 
AA Ile Gln Lys Leu Val Gly Lys Leu Asn Trp Ala Ser Gln Ile Try Pro 
257 258 259 260 261 262 263 264 265 266 267 268 269 270 271 272 
RT6 
819 822 825 828 831 834 837 840 843 846 849 852 855 858 861 864 
nt GGG ATT AAA GTA AGG CAA TTA TGT AAA CTC CTT AGA GGA ACC AAA GCA 
AA Gly Ile Lys Val Arg Gln Leu Cys Lys Leu Leu Arg Gly Thr Lys Ala 
273 274 275 276 277 278 279 280 281 282 283 284 285 286 287 288 
867 870 873 876 879 882 885 888 891 894 897 900 903 906 909 912 
nt CTA ACA GAA GTA ATA CCA CTA ACA GAA GAA GCA GAG CTA GAA CTG GCA 
AA Leu Thr Glu Val Ile Pro Leu Thr Glu Glu Ala Glu Leu Glu Leu Ala 
289 290 291 292 293 294 295 296 297 298 299 300 301 302 303 304 
915 918 921 924 927 930 933 936 939 942 945 948 951 954 957 960 
nt GAA AAC AGA GAG ATT CTA AAA GAA CCA GTA CAT GGA GTG TAT TAT GAC 
AA Glu Asn Arg Glu Ile Leu Lys Glu Pro Val His Gly Val Tyr Tyr Asp 
305 306 307 308 309 310 311 312 313 314 315 316 317 318 319 320 
963 966 969 972 975 978 981 984 987 990 993 996 999 1002 1005 1008 
nt CCA TCA AAA GAC TTA ATA GCA GAA ATA CAG AAG CAG GGG CAA GGC CAA 
AA Pro Ser Lys Asp Leu Ile Ala Glu Ile Gln Lys Gln Gly Gln Gly Gln 
321 322 323 324 325 326 327 328 329 330 331 332 333 334 335 336 
1011 1014 1017 1020 1023 1026 1029 1032 1035 1038 1041 1044 1047 1050 1053 1056 
nt TGG ACA TAT CAA ATT TAT CAA GAG CCA TTT AAA AAT CTG AAA ACA GGA 
AA Trp Thr Tyr Gln Ile Tyr Gln Glu Pro Phe Lys Asn Leu Lys Thr Gly 
337 338 339 340 341 342 343 344 345 346 347 348 349 350 351 352 
MluI 
1059 1062 1065 1068 1071 1074 1077 1080 1083 1086 1089 1092 1095 1098 1101 1104 
nt AAA TAT GCA AGA ACG CGT GGT GCC CAC ACT AAT GAT GTA AAA CAA TTA 
AA Lys Tyr Ala Arg Thr Arg Gly Ala His Thr Asn Asp Val Lys Gln Leu 
353 354 355 356 357 358 359 360 361 362 363 364 365 366 367 368 
1107 1110 1113 1116 1119 1122 1125 1128 1131 1134 1137 1140 1143 1146 1149 1152 
nt ACA GAG GCA GTG CAA AAA ATA ACC ACA GAA AGC ATA GTA ATA TGG GGA 
AA Thr Glu Ala Val Gln Lys Ile Thr Thr Glu Ser Ile Val Ile Trp Gly 
369 370 371 372 373 374 375 376 377 378 379 380 381 382 383 384 
 
 103 
1155 1158 1161 1164 1167 1170 1173 1176 1179 1182 1185 1188 1191 1194 1197 1200 
nt AAG ACT CCT AAA TTT AAA CTA CCC ATA CAA AAG GAA ACA TGG GAA ACA 
AA Lys Thr Pro Lys Phe Lys Leu Pro Ile Gln Lys Glu Thr Trp Glu Thr 
385 386 387 388 389 390 391 392 393 394 395 396 397 398 399 400 
1203 1206 1209 1212 1215 1218 1221 1224 1227 1230 1233 1236 1239 1242 1245 1248 
nt TGG TGG ACA GAG TAT TGG CAA GCC ACC TGG ATT CCT GAG TGG GAG TTT 
AA Trp Trp Thr Glu Tyr Trp Gln Ala Thr Trp Ile Pro Glu Trp Glu Phe 
401 402 403 404 405 406 407 408 409 410 411 412 413 414 415 416 
1251 1254 1257 1260 1263 1266 1269 1272 1275 1278 1281 1284 1287 1290 1293 1296 
nt GTC AAT ACC CCT CCT TTA GTG AAA TTA TGG TAC CAG TTA GAG AAA GAA 
AA Val Asn Thr Pro Pro Leu Val Lys Leu Trp Tyr Gln Leu Glu Lys Glu 
417 418 419 420 421 422 423 424 425 426 427 428 429 430 431 432 
1299 1302 1305 1308 1311 1314 1317 1320 1323 1326 1329 1332 1335 1338 1341 1344 
nt CCC ATA GTA GGA GCA GAA ACG TTC TAT GTA GAT GGG GCA GCT AGC AGG 
AA Pro Ile Val Gly Ala Glu Thr Phe Tyr Val Asp Gly Ala Ala Ser Arg 
433 434 435 436 437 438 439 440 441 442 443 444 445 446 447 448 
1347 1350 1353 1356 1359 1362 1365 1368 1371 1374 1377 1380 1383 1386 1389 1392 
nt GAG ACT AAA TTA GGA AAA GCA GGA TAT GTT ACT AAT AGA GGA AGA CAA 
AA Glu Thr Lys Leu Gly Lys Ala Gly Tyr Val Thr Asn Arg Gly Arg Gln 
449 450 451 452 453 454 455 456 457 458 459 460 461 462 463 464 
RT8 
1395 1398 1401 1404 1407 1410 1413 1416 1419 1422 1425 1428 1431 1434 1437 1440 
nt AAA GTT GTC ACC CTA ACT GAC ACA ACA AAT CAG AAG ACT GAG TTA CAA 
AA Lys Val Val Thr Leu Thr Asp Thr Thr Asn Gln Lys Thr Glu Leu Gln 
465 466 467 468 469 470 471 472 473 474 475 476 477 478 479 480 
XbaI 
1443 1446 1449 1452 1455 1458 1461 1464 1467 1470 1473 1476 1479 1482 1485 1488 
nt GCA ATT CAT CTA GCT TTG CAG GAT TCG GGT CTA GAA GTA AAT ATA GTA 
AA Ala Ile His Leu Ala Leu Gln Asp Ser Gly Leu Glu Val Asn Ile Val 
481 482 483 484 485 486 487 488 489 490 491 492 493 494 495 496 
1491 1494 1497 1500 1503 1506 1509 1512 1515 1518 1521 1524 1527 1530 1533 1536 
nt ACA GAC TCA CAA TAT GCA TTA GGA ATC ATT CAA GCA CAA CCA GAT AAA 
AA Thr Asp Ser Gln Tyr Ala Leu Gly Ile Ile Gln Ala Gln Pro Asp Lys 
497 498 499 500 501 502 503 504 505 506 507 508 509 510 511 512 
1539 1542 1545 1548 1551 1554 1557 1560 1563 1566 1569 1572 1575 1578 1581 1584 
nt AGT GAA TCA GAG TTA GTC AAT CAA ATA ATA GAG CAG TTA ATA AAA AAG 
AA Ser Glu Ser Glu Leu Val Asn Gln Ile Ile Glu Gln Leu Ile Lys Lys 
513 514 515 516 517 518 519 520 521 522 523 524 525 526 527 528 
1587 1590 1593 1596 1599 1602 1605 1608 1611 1614 1617 1620 1623 1626 1629 1632 
nt GAA AAG GTC TAT CTG GCA TGG GTA CCA GCA CAC AAA GGA ATT GGA GGA 
AA Glu Lys Val Tyr Leu Ala Trp Val Pro Ala His Lys Gly Ile Gly Gly 
529 530 531 532 533 534 535 536 537 538 539 540 541 542 543 544 
NgoMIV 
1635 1638 1641 1644 1647 1650 1653 1656 1659 1662 1665 1668 1671 1674 1677 1680 
nt AAT GAA CAA GTA GAT AAA TTA GTC AGT GCC GGC ATC AGG AAA GTA CTA 
AA Asn Glu Gln Val Asp Lys Leu Val Ser Ala Gly Ile Arg Lys Val Leu 
545 546 547 548 549 550 551 552 553 554 555 556 557 558 559 560 
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APPENDIX B 
B.1 NUCLEIC ACID OLIGOMERS 
The studies described in this thesis required the use of many nucleic acid oligomers for 
molecular cloning, Sanger DNA sequencing, site-directed mutagenesis, substrate 
primer/templates, etc. All oligomers are described in Appendix B. 
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B.1.1 Site-Directed Mutagenesis Primers: 
All RT site-directed mutants are designed and created from HIV-1xxLAI-MO, Appendix A. 
 
L74V 
F: 5’-AGTACTAAATGGAGAAAAGTAGTAGATTTCAGAGAACTTAATAAGAGAACTC-3’ 
R: 5’-GAGTTCTCTTATTAAGTTCTCTGAGATATACTACTTTTCTCCATTTAGTACT-3’ 
 
F77L  
F: 5’-AGTACTAAATGGAGAAAATTAGTAGATCTCAGAGAACTTAATAAGAGAACTC-3’ 
R: 5’-GAGTTCTCTTATTAAGTTATCTGAGATCTACTACTTTTCTCCATTTAGTACT-3’ 
 
F77L/L74V 
F: 5’-AGTACTAAATGGAGAAAAGTAGTAGATCTCAGAGAACTTAATAAGAGAACTC-3’ 
R: 5’-GAGTTCTCTTATTAAGTTCTCTGAGATCTACTACTTTTCTCCATTTAGTACT-3’ 
 
V75I 
F: 5’-CATAAAGAAAAAAGACAGTACTAAATGGAGAAAATTAATAGATTTCAGAGAACTTAATAA-3’ 
R: 5’-TTATTAAGTTCTCTGAAATCTATTAATTTTCTCCATTTAGTACTGTCTTTTTTCTTTATG-3’ 
 
E122K 
F: 5’-GTGATGCATATTTTTCAGTTCCCTTAGATAAAGACTTCAGGAAGTA-3’ 
R: 5’-TACTTCCTGAAGTCTTTATCTAAGGGAACTGAAAAATATGCATCAC-3’ 
 
L214F 
F: 5’-CTGTTGAGGTGGGGATTTACCACACCAGACAAAAAAC-3’ 
R: 5’-GTTTTTTGTCTGGTGTGGTAAATCCCCACCTCAACAG-3’ 
 
N447S 
F: 5’-CTATGTAGATGGGGCAGCTAGCAGGGAGACTAAATTA-3’ 
R: 5’-TAATTTAGTCTCCCTGCTAGCTGCCCCATCTACATAG-3’ 
 
K476N: 
F: 5'-CCTAACTGACACAACAAATCAGAATACTGAGTTACAAGCAATTCATC-3' 
R: 5'-GATGAATTGCTTGTAACTCAGTATTCTGATTTGTTGTGTCAGTTAGG-3' 
 
V518I 
F: 5'-GCACAACCAGATAAAAGTGAATCAGAGTTAATCAATCAAATAATAGAG-3' 
R: 5'-CTCTATTATTTGATTGATTAACTCTGATTCACTTTTATCTGGTTGTGC-3' 
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B.1.2 Reversion Site-Directed Mutagenesis Primers: 
All RT single genome sequence clone isolates described below contained either of the 
following backgrounds in addition to the HIV-1xxLAI-MO genotype, Appendix A: 
SGS3.4 (L74V/F77L/V106I/L214F/R277K/K476N)  
SGS1.2 (L74V/F77L/V106I/E122K/L214F/R277K/K447N/V518I/V531I) 
 
SGS3.4ΔV74 
F: 5'-CATAAAGAAAAAAGACAGTACTAAATGGAGAAAATTAGTAGATCTCAGAGAAC-3' 
R: 5'-GTTCTCTGAGATCTACTAATTTTCTCCATTTAGTACTGTCTTTTTTCTTTATG-3' 
 
SGS3.4ΔL77 
F: 5'-GTACTAAATGGAGAAAAGTAGTAGATTTCAGAGAACTTAATAAGAGAACTC-3' 
R: 5'-GAGTTCTCTTATTAAGTTCTCTGAAATCTACTACTTTTCTCCATTTAGTAC-3' 
 
SGS3.4ΔI106 
F: 5'-CGCAGGGTTAAAAAAGAAAAAATCAGTAACAGTACTGGATGTGG-3' 
R: 5'-CCACATCCAGTACTGTTACTGATTTTTTCTTTTTTAACCCTGCG-3' 
 
SGS3.4ΔF214 
F: 5'-ACATCTGTTGAGGTGGGGATTAACCACACCAGAC-3' 
R: 5'-GTCTGGTGTGGTTAATCCCCACCTCAACAGATGT-3' 
 
SGS3.4ΔR277 
F: 5'-TCAGATTTACCCAGGGATTAAAGTAAGGCAATTATGTAAACTCCTT-3' 
R: 5'-AAGGAGTTTACATAATTGCCTTACTTTAATCCCTGGGTAAATCTGA-3' 
 
SGS3.4ΔN476 
F: 5'-CTAACTGACACAACAAATCAGAAGACTGAGTTACAAGCAATTCAT-3' 
R: 5'-ATGAATTGCTTGTAACTCAGTCTTCTGATTTGTTGTGTCAGTTAG-3' 
 
SGS1.2ΔK122 
F: 5'-TGGGTGATGCATATTTTTCAGTTCCCTTAGATGAGGACTTCAGGAAGTATAC-3' 
R: 5'-GTATACTTCCTGAAGTCCTCATCTAAGGGAACTGAAAAATATGCATCACCCA-3' 
 
SGS1.2ΔN447 
F: 5'-CTATGTAGATGGGGCAGCTAGCAGGGAGACTAAATTA-3' 
R: 5'-TAATTTAGTCTCCCTGCTAGCTGCCCCATCTACATAG-3' 
 
SGS1.2ΔV518 
F: 5'-GCACAACCAGATAAAAGTGAATCAGAGTTAGTCAATCAAATAATAGAG-3' 
R: 5'-CTCTATTATTTGATTGACTAACTCTGATTCACTTTTATCTGGTTGTGC-3' 
 
SGS1.2ΔV518 
F: 5'-AGCAGTTAATAAAAAAGGAAAAGGTCTATCTGGCATGGGTACCAG-3' 
R: 5'-CTGGTACCCATGCCAGATAGACCTTTTCCTTTTTTATTAACTGCT-3' 
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B.1.3 Substrate Template/Primer for Biochemical Analysis: 
All T/Ps were annealed and labeled as described in section 4.4 Material and Methods. 
 
P19:              3’-GGAAACCTACCACGATGTT-5’  
T36: 5’-AGAGCCCCCGAGACCTTTGGATGGTGCTACAAGCT-3’ 
 
P20:                             3’-AGAGATCGTCACCGCGGGCT-5’ 
T36: 5’-CTCAGACCCTTTTAGTCAGAATGGAAAATCTCTAGCAGTGGCGCCCGAACAG-3’ 
 
P23:     3’-CTCTGGAAACCTACCACGATGTT-5’ 
T36: 5’-CTCAGACCCTTTTAGTCAGAATGGAAAATCTCTAGCAGTGGCGCCCGAACAG-3’ 
 
P23?:      3’-CdTdCdTdGdGdAdAdAdCdCdTdAdCdCdAdCdGdAdTdGdTdT-5’ 
T36?: 5’-rCrArGrArGrCrCrCrCrCrGrArGrArCrCrUrUrUrGrGrArUrGrGrUrGrCrUrArCrArArGrCrU-3’ 
?DNA sequence 
?RNA sequence 
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B.1.4 Sequencing Primers (all forward): 
P6RT is a forward direction primer and is designed to specifically anneal 5’-upstream the 
RT cloning site within the expression and cloning plasmid p6HRTxxLAI-MO, 
 
P6RT 
5’-GATCCCAGCTTCCCATT-3’ 
 
 
All primers listed below sequence in the forward direction and are designed to specifically 
anneal within the RT gene of the HIV-1xxLAI-MO sequence, Appendix A. 
 
RT-2066(+) 
5’-GGACCTACACCTGTCAAC-3’ 
 
RT-S2 
5’-GTTCCCTTAGATGAAGAC-3’ 
 
RT+6 
5’-GAGGAACCAAAGCACTAA-3’ 
 
RT+8 
5’-CACCCTAACTGACACAAC-3’ 
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B.1.5 Cloning Primers: 
The primers described below are designed to bind and add restriction sites in the RT HIV-
1xxLAI-MO sequence, Appendix A [374]. 
  
3D 1989Bcl(+) 
5’-GTTTTATCAAAGTAAGACAGTATGATCAGATAC-3’ 
 
3D BstBI(+) 
5’-GTATTATGACCCTTCGAAAGACTTAATAG-3’ 
 
3D BstBI(-) 
5’-CTATTAAGTCTTTCGAAGGGTCATAATAC-3’ 
 
3D HpaI(+) 
5’-GAGTTTGTTAACACCCCTCCTTTAGT-3’ 
 
3D HpaI(-) 
5’-GAGGGGTGTTAACAAACTCCCAC-3’ 
 
3D SgrAI(-) 
5’-CTACCACCGGTGGCAGGTTA-3’ 
 
4232(-) 
5’-CCTTGACTTTGGGGATTGTAGGGAA-3’ 
 
Bcl(+) 
5’-AGGAAGATGGAAACCAAAAATGATAG-3’ 
 
The primers described below are designed to specifically anneal to sites in the PRO and IN 
genes of the HIV-1xxLAI-MO sequence for amplification of full-length RT. 
 
PRO-for 
5’-GCTCTATTAGATACAGGAGCAGATGAT-3’ 
 
IN-rev 
5’-CCTTCTAAATGTGTACAATCTAGTTGCCAT-3’ 
 
RT3908(-) 
5’-CACAGCTGGCTACTATTTCTTTTG-3’ 
 
Whole RT-U 
5’-AAGCTATAGGTACAGTATTAGTAGGACCTAC-3’ 
 
Whole RT-L 
5’-TGCTCTCCAATTACTGTGATATTTCTCA-3 
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